Fortress Biotech (FBIO) 10-Q 9 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 09, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		50,527,604

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 144,344	$ 88,294
Accounts receivable	3,336	1,830
Short-term investment (certificate of deposit)	20,038	0
Cash deposits with clearing organizations	1,040	1,030
Receivables from broker-dealers and clearing organizations	2,813	3,357
Forgivable loans receivable	1,397	1,712
Securities owned, at fair value	3,406	2,357
Inventory	299	203
Other receivables - related party	1,605	1,790
Prepaid expenses and other current assets	11,902	9,061
Total current assets	190,180	109,634
Property and equipment, net	7,329	7,376
Restricted cash	15,860	15,860
Long-term investments, at fair value	903	1,414
Intangible asset - license	16,533	17,408
Goodwill	18,645	18,645
Other assets	396	394
Total assets	249,846	170,731
Current liabilities
Accounts payable and accrued expenses	24,995	23,871
Accrued expense - related party	78	0
Accrued commissions and payroll payable	11,613	11,940
Deferred clearing and marketing credits	891	995
Securities sold, not yet purchased, at fair value	77	298
Interest payable	142	88
Interest payable - related party	326	77
Notes payable, short-term	3,007	1,000
Subsidiary convertible note, short-term, at fair value	3,211	1,031
Contingent consideration payable	630	424
Warrants issued in 2017 and issuable in 2016 - National	8,190	14,359
Contingently issuable liabilities	0	1,682
Derivative warrant liability	91	481
Other current liabilities	217	319
Total current liabilities	53,468	56,565
Notes payable, long-term (net of debt discount of $4,723 and $2,009 at June 30, 2017 and December 31, 2016, respectively)	39,274	22,528
Subsidiary convertible note, long-term, at fair value	1,462	3,656
Other long-term liabilities	5,026	5,014
Total liabilities	99,230	87,763
Commitments and contingencies
Stockholders' equity
Common stock, $.001 par value, 100,000,000 shares authorized, 50,463,245 and 48,932,023 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	50	49
Common stock issuable, 45,818 and 0 shares as of June 30, 2017 and December 31, 2016, respectively	189	0
Additional paid-in-capital	346,630	283,697
Accumulated deficit	(274,598)	(245,251)
Total stockholders' equity attributed to the Company	72,271	38,495
Non-controlling interests	78,345	44,473
Total stockholders' equity	150,616	82,968
Total liabilities and stockholders' equity	249,846	170,731
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Convertible preferred stock, $.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Discount	$ 4,723	$ 2,009
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	50,463,245	48,932,023
Common Stock, shares outstanding	50,463,245	48,932,023
Common Stock, Shares Subscribed but Unissued	45,818	0
Series C Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	129,767	129,767
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue
Revenues	$ 50,697	$ 2,230	$ 95,379	$ 2,890
Operating expenses
Cost of goods sold - product revenue	878	324	1,347	324
Research and development - licenses acquired	1,800	2,060	3,094	2,143
General and administrative	8,524	6,637	16,509	12,666
Total operating expenses	73,890	17,366	136,149	33,117
Loss from operations	(23,193)	(15,136)	(40,770)	(30,227)
Other income (expenses)
Interest income	190	77	326	152
Interest expense and financing fee	(1,380)	(529)	(2,078)	(1,149)
Change in fair value of derivative liabilities	1,452	0	5,794	(89)
Change in fair value of subsidiary convertible note	(188)	0	(285)	0
Change in fair value of investments	157	(801)	(511)	(1,719)
Other income	13	0	13	0
Total other income (expenses)	244	(1,253)	3,259	(2,805)
Net loss	(22,949)	(16,389)	(37,511)	(33,032)
Net loss attributable to non-controlling interests	(5,584)	(3,911)	(8,164)	(8,349)
Net loss attributable to common stockholders	$ (17,365)	$ (12,478)	$ (29,347)	$ (24,683)
Basic and diluted net loss per common share	$ (0.43)	$ (0.31)	$ (0.73)	$ (0.62)
Weighted average common shares outstanding—basic and diluted	40,551,844	39,867,724	40,457,524	39,762,956
Parent Company [Member]
Revenue
Product revenue, net	$ 4,054	$ 981	$ 6,139	$ 1,364
Revenue - from a related party	350	1,249	1,043	1,526
Revenues	4,404	2,230	7,182	2,890
Operating expenses
Cost of goods sold - product revenue	878	324	1,347	324
Research and development	11,683	6,347	18,793	14,100
Research and development - licenses acquired	1,800	2,060	3,094	2,143
General and administrative	11,134	8,635	21,386	16,550
Total operating expenses	25,495	17,366	44,620	33,117
National Holdings Corporation [Member]
Revenue
Commissions	23,993	0	48,499	0
Net dealer inventory gains	2,366	0	4,877	0
Investment banking	10,592	0	17,653	0
Investment advisory	3,490	0	6,875	0
Interest and dividends	675	0	1,391	0
Transfer fees and clearing services	1,687	0	4,185	0
Tax preparation and accounting	3,144	0	4,000	0
Other	346	0	717	0
Revenues	46,293	0	88,197	0
Operating expenses
Commissions, compensation and fees	41,762	0	79,020	0
Clearing fees	618	0	1,356	0
Communications	682	0	1,404	0
Occupancy	936	0	1,944	0
Licenses and registration	427	0	832	0
Professional fees	991	0	2,254	0
Interest	4	0	8	0
Depreciation and amortization	500	0	1,006	0
Other administrative expenses	2,475	0	3,705	0
Total operating expenses	$ 48,395	$ 0	$ 91,529	$ 0

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders’ Equity - 6 months ended Jun. 30, 2017 - USD ($) $ in Thousands	Total	Common Stock [Member]	Common Shares Issuable [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit	Non-Controlling Interests [Member]
Balance at Dec. 31, 2016	$ 82,968	$ 49	$ 0	$ 283,697	$ (245,251)	$ 44,473
Balance (in shares) at Dec. 31, 2016		48,932,023
Exercise of options for cash	$ 27	$ 0	0	27	0	0
Exercise of options for cash (in shares)	20,000	20,000
Stock-based compensation expense	$ 7,736	$ 0	0	7,736	0	0
Issuance of restricted stock	0	$ 1	0	(1)	0	0
Issuance of restricted stock (in shares)		1,489,146
Issuance of subsidiaries' common shares for license expenses	1,712	$ 0	0	1,712	0	0
Issuance of common stock under ESPP	42	$ 0	0	42	0	0
Issuance of common stock under ESPP (in shares)		22,076
Subsidiaries’ offering, net	92,991	$ 0	0	92,991	0	0
Debt discount related to Opus Credit Facility	201	0	0	201	0	0
Issuance of warrants by subsidiary in conjunction with NSC debt	750	0	0	750	0	0
Issuance of warrants in connection with 2017 promissory notes	1,197	0	0	1,197	0	0
Conversion of subsidiaries notes payable	314	0	0	314	0	0
Common shares issuable for NHLD interest expense	189	0	189	0	0	0
Non-controlling interest in subsidiaries’	0	0	0	(42,036)	0	42,036
Net loss attributable to non-controlling interest	(8,164)	0	0	0	0	(8,164)
Net loss attributable to common stockholders	(29,347)	0	0	0	(29,347)	0
Balance at Jun. 30, 2017	$ 150,616	$ 50	$ 189	$ 346,630	$ (274,598)	$ 78,345
Balance (in shares) at Jun. 30, 2017		50,463,245

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows from Operating Activities:
Net Loss	$ (37,511)	$ (33,032)
Reconciliation of net loss to net cash used in operating activities:
Depreciation expense	543	74
Amortization expense of intangible asset	819	0
Amortization of debt discount	702	423
Amortization of product revenue license fee	267	21
Amortization of forgivable loans to registered representatives	362	0
Amortization of deferred clearing credit	(104)	0
Stock-based compensation expense	7,736	5,889
Recovery for doubtful accounts	(256)	0
Common shares issuable for NHLD interest expense	189	0
Change in fair value of investments	511	1,719
Change in fair value of derivative liabilities	(5,794)	89
Change in fair value of subsidiary convertible note	285	0
Research and development-licenses acquired, expense	3,095	2,143
Change in fair value of subsidiaries’ assets and liabilities	10	249
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Cash deposits with clearing organizations	(10)	0
Accounts receivable	(1,506)	(967)
Receivables from broker-dealers and clearing organizations	544	0
Forgivable loans receivable	(47)	0
Securities owned, at fair value	(1,049)	0
Inventory	(96)	(100)
Other receivables - related party	185	(2,414)
Prepaid expenses and other current assets	(2,590)	195
Accounts payable and accrued expenses	(1,721)	3,571
Accrued expense - related party	24	0
Securities sold, but not yet purchased, at fair value	(221)	0
Interest payable	3	(1)
Interest payable - related party	259	0
Other long-term liabilities	2	3,122
Net cash used in operating activities	(35,369)	(19,019)
Cash Flows from Investing Activities:
Purchase of research and development licenses	(665)	(2,095)
Purchase of property and equipment	(454)	(4,300)
Purchase of license	0	(350)
Purchase of short-term investment (certificates of deposit)	(20,038)	0
Security deposits refund	3	0
Security deposits collected	0	(1)
Acquisition of business - National	(19)	0
Collection on notes receivable - disposal of Gilman branches	8
Investment in Origo Acquisition Corp.	0	(175)
Net cash used in investing activities	(21,165)	(6,921)
Cash Flows from Financing Activities:
Proceeds from subsidiaries' offering	93,853	570
Payment of costs related to subsidiaries' offering	(862)	0
Proceeds from at-the-market offering	0	434
Payment of cost related to at-the-market offering	0	(49)
Proceeds from NSC note	18,967	0
Payment of debt issuance costs associated with NSC Note	(1,939)	0
Payment of NSC note	0	(2,792)
Proceeds from exercise of stock options	27	0
Proceeds from issuance of common stock under ESPP	42	81
Proceeds from subsidiaries' Convertible Note	0	1,000
Payment of debt issuance costs associated with subsidiaries' Convertible Note	(4)	(150)
Proceeds from Opus Credit Facility	2,500	0
Net cash provided by (used in) financing activities	112,584	(906)
Net increase (decrease) in cash and cash equivalents	56,050	(26,846)
Cash and cash equivalents at beginning of period	88,294	98,182
Cash and cash equivalents at end of period	144,344	71,336
Supplemental disclosure of cash flow information:
Cash paid for interest	58	158
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	1	2
Issuance of warrants by subsidiary in conjunction with NSC debt	750	0
Issuance of warrants in connection with 2017 Subordinated Note Financing	1,197	0
Issuance of warrants in connection with subsidiaries' Convertible Note	0	99
Debt discount related to Opus Credit Facility	201	0
Unpaid debt offering cost	79	0
Issuance of subsidiaries common shares for license	0	48
Common shares issuable for license acquired	1,682	0
Conversion of subsidiaries notes payable	314	0
Fixed assets (acquired but not paid)	42	0
Business acquired:
Identifiable intangible asset acquired	211	0
Contingent consideration payable	(192)	0
Cash paid	$ 19	$ 0

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also referred to as the “Fortress Companies.” Additionally, the Company has a controlling interest in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, referred to as “NHLD” or “National”). In addition to its internal development programs, the Company leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. The Company and the Fortress Companies may seek licenses, acquisitions, partnerships, joint ventures and/or public and private financings (including financings facilitated by NHLD) to accelerate and provide additional funding to support their research and development programs. As of June 30, 2017, in addition to NHLD, the Company has several consolidated Fortress Companies, some of which contain product licenses, including Avenue Therapeutics, Inc. (“Avenue”), Cellvation, Inc. (“Cellvation”), Journey Medical Corporation (“Journey or “JMC”), Coronado SO Co. (“Coronado SO”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Mustang Bio, Inc. (“Mustang”), Helocyte, Inc. (“Helocyte”), Escala Therapeutics, Inc. (“Escala”), CB Securities Corporation (which holds investments classified as cash and cash equivalents), Caelum Biosciences, Inc. (“Caelum”) and Cyprium Therapeutics, Inc. (“Cyprium”). In addition to the foregoing companies, Fortress also maintains ownership positions in subsidiaries with minimal activity, including Innmune Limited.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year for each of the Company, Avenue, Checkpoint, Mustang and National. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2017, from which the Company derived the balance sheet data at December 31, 2016, as well as National’s Form 10-K, filed with SEC on December 29, 2016 and their Form 10-Q, filed with the SEC on May 15, 2017, Checkpoint’s Forms 10-K and 10-K/A, filed with the SEC on March 17, 2017 and March 21, 2017, respectively, Mustang’s Form 10-K, filed with the SEC on March 31, 2017, and Avenue’s Form 10-12G/A, filed with the SEC on March 27, 2017. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: NHLD, Innmune Limited, Coronado SO, Cyprium, Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang, Helocyte, Cellvation and Caelum. All intercompany balances and transactions have been eliminated. The National assets acquired and liabilities assumed and revenues and expenses are reported on a one quarter lag. Therefore, the National assets acquired and liabilities assumed included in these consolidated financial statements as of June 30, 2017 are actually the assets and liabilities as of March 31, 2017 and the revenues and expenses included in these consolidated financial statements for the quarter ending June 30, 2017 are actually the revenues and expenses for the quarter ending March 31, 2017. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Form 10-K filed with the SEC on March 16, 2017, with the exception of the policies listed below. The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at June 30, 2017 and at December 31, 2016 consisted of cash, money market funds and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities. Items with maturities greater than 90 days but less than one year at the time of acquisition are considered short-term investments. The company classifies its certificates of deposit as held to maturity in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) 320, Investments – Debt and Equity Securities 20.0 20.0 250,000 Investments consist of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the Company’s certificates of deposit approximated fair value. In March 2016, the FASB issued Accounting Standards Update ("ASU") 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception

National Holdings Corporation A

National Holdings Corporation Acquisition – Intangible Assets	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
National Holdings Corporation Acquisition - Intangible Assets	3. National Holdings Corporation Acquisition – Intangible Assets On September 9, 2016, the Company, purchased approximately 56.6 0.02 3.25 In connection with the purchase, the Company recognized $ 18.6 Useful life Trademark 10 years Customer lists 10 years Intangible assets at December 31, 2016 $ 15,991 Amortization expense (819) Intangible assets at June 30, 2017 $ 15,172 Total Six Months Ended December 31, 2017 $ 831 Year Ended December 31, 2018 1,649 Year Ended December 31, 2019 1,649 Year Ended December 31, 2020 1,654 Year Ended December 31, 2021 1,649 Thereafter 7,740 Total $ 15,172 The Company reviews its finite-lived intangible assets for impairment when events or changes in circumstances indicate that the carrying amount of a finite-lived intangible asset may not be recoverable. Recoverability of a finite-lived intangible asset is measured by a comparison of its carrying amount to the undiscounted future cash flows expected to be generated by the asset. If the asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no indicators of impairment during the six months ended June 30, 2017.

Broker-Dealers and Clearing Org

Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2017
Brokers and Dealers [Abstract]
Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities	4. Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities At March 31, 2017, National’s receivables of $ 2.8 6.1 0.5

Forgivable Loans Receivable

Forgivable Loans Receivable	6 Months Ended
	Jun. 30, 2017
Forgivable Loans Receivable [Abstract]
Forgivable Loans Receivable	5. Forgivable Loans Receivable From time to time, National's operating subsidiaries may make loans, evidenced by promissory notes, primarily to newly recruited independent financial advisors as an incentive for their affiliation. The notes receivable balance is comprised of unsecured non-interest-bearing and interest-bearing loans (interest ranging up to 9 National provides an allowance for doubtful accounts on the notes based on historical collection experience and continually evaluates the receivables for collectability and possible write-offs where a loss is deemed probable. As of March 31, 2017, no allowance for doubtful accounts was required. There were no unamortized forgivable loans outstanding at March 31, 2017 attributable to registered representatives who ended their affiliation with National’s subsidiaries prior to the fulfillment of their obligation

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Estimated Useful June 30, December 31, Lives (in years) 2017 2016 Computer equipment 3 $ 517 $ 440 Furniture and fixtures 5 931 821 Leasehold improvements Various 5,351 5,396 Total property and equipment 6,799 6,657 Less: accumulated depreciation (801) (445) Property and equipment, net $ 5,998 $ 6,212 Fortress's depreciation expense for the three months ended June 30, 2017 and 2016, was approximately $ 180 82 356 86 March 31, Estimated Useful 2017 Lives (in years) Equipment $ 861 5 Furniture and fixtures 82 5 Leasehold improvements 335 Lesser of useful life or term of lease Capital leases (primarily composed of computer equipment) 276 5 Total property and equipment 1,554 Less: accumulated depreciation (223) Property and equipment, net $ 1,331

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. Laser Device for Treatment of Migraine Headache On March 17, 2014, the Company invested $250,000 for a 35% ownership position in a third-party company developing a laser device to treat migraine headaches. The Company elected the fair value option for recording this investment. In conjunction with this investment, the Company received 13,409,962 Class A Preferred Units in the third-party company, representing 83% of the total 16,091,954 Class A Preferred Units. The fair value of this investment was $0.3 million as of June 30, 2017 and December 31, 2016. The value of the Company’s investment was determined based on a valuation which takes into consideration, when applicable, cash paid, cost of the investment, market participant inputs, estimated cash flows based on entity specific criteria, purchase multiples paid in other comparable third-party transactions, market conditions, liquidity, operating results and other qualitative and quantitative factors. Based on these inputs at June 30, 2017, the fair value of the Company’s investment approximated cost. Origo Acquisition Corporation (formerly CB Pharma Acquisition Corporation) On December 19, 2016, Origo Acquisition Corporation (“Origo”) entered into a merger agreement (“Origo Merger Agreement”) with Aina Le’a Inc. (“Aina Le’a”), a residential and commercial real estate developer in Hawaii. On February 17, 2017, Origo sent a letter, as supplemented on February 22, 2017 (the “Termination Letter”), to Aina Le’a terminating the Origo Merger Agreement. On March 10, 2017, Origo’s shareholders approved an amendment to Origo’s organizational documents extending the date by which Origo must consummate a merger to September 12, 2017. As of June 30, 2017, the Company valued its investment in Origo, a publicly traded company, utilizing the following assumptions: probability of a successful business combination of 24.3%, and no dividend rate, which yielded an instrument value upon business combination of $9.73 per ordinary share for the private placement shares. The rights and warrants were valued utilizing a binomial-lattice model at a value of $0.24 for each right and $0.18 for each warrant. Based upon the valuation, the Company recorded a decrease in fair-value of investment of $0.5 million for the six months ended June 30, 2017. At June 30, 2017, the fair value of the Company’s investment in Origo was, $0.7 million. The Company’s working capital note with Origo of $0.3 million can be converted to stock upon a successful business combination. Contingently Issuable Warrant Pursuant to the Company’s promissory note with NSC of March 2015, as amended in July 2015 (the “NSC Note”), if the Company transfers any proceeds from the NSC Note to a Fortress Company, such Fortress Company will issue to NSC Biotech Venture Fund I LLC a new promissory note on identical terms as the NSC Note and NSC Biotech Venture Fund I LLC will also receive a warrant to purchase a number of shares of such Fortress Company’s stock equal to 25% of the outstanding Fortress Company note divided by the lowest price for which the Fortress Company sells its equity in its first third party financing. The warrants issued will have a term of 10 years and an exercise price equal to the par value of the Fortress Company’s common stock and are accounted for in accordance with ASC 815, Derivatives and Hedging. Avenue classified the fair value of the contingently issuable warrants granted in connection with the transfer from Fortress of $3.0 million to Avenue under the NSC Note as a derivative liability as there was a potential that Avenue would not have a sufficient number of authorized common shares available to settle these instruments. On June 30, 2017, Avenue closed on an Initial Public Offering (“IPO”) raising gross proceeds of $37.9 million and issuing 6.3 million commons shares at $6.00 per share. As such, pursuant to the terms of Avenue’s $3.0 million NSC Note, Avenue issued to National a warrant to purchase 125,000 of its common shares at par. The issuance of the warrant relates to the completion of Avenue’s IPO in which Avenue’s raised gross proceeds from a third-party party exceeding five times the value of the debt. Upon the issuance of the warrant by Avenue, the Company was removed as the guarantor on the note. ($ in thousands) Avenue’s Beginning balance at January 1, 2017 $ 302 Conversion into common shares (750 ) Change in fair value 448 Ending balance at June 30, 2017 $ - Avenue Warrant Liabilities On December 30, 2016, Avenue held a closing of the sale of convertible promissory notes. In the closing, WestPark Capital, Inc., the placement agent (“WestPark”), received a warrant (the “WestPark Warrant”) to purchase the number of shares of Avenue’s common stock equal to $10,000 divided by the price per share at which any note sold to investors first converts into Avenue’s common stock. The WestPark Warrant has a ten-year term. Avenue’s WestPark Warrant liability was measured at fair value using a Monte Carlo simulation valuation methodology. Additionally, on June 30, 2017, in connection with Avenue’s IPO, Avenue issued 2,488 warrants to purchase common shares of Avenue at $4.02, a 33% discount to the IPO price of $6.00 to Westpark Capital in connection with their role as placement agent for Avenue’s 2016 Convertible Notes, which automatically converted to common shares of Avenue upon completion of the IPO. ($ in thousands) Avenue’s Beginning balance at January 1, 2017 $ 12 Conversion into common shares (15 ) Change in fair value 3 Ending balance at June 30, 2017 $ - Helocyte Warrant Liabilities The fair value of Helocyte’s warrant liability was measured at fair value using a Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (level 3 inputs) used in measuring Helocyte’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of June 30, 2017 is as follows: June 30, Risk-free interest rate 1.720% -1.792 % Expected dividend yield - % Expected term in years 4.00 - 4.42 Expected volatility 70.0 % Strike price $ 0.44 ($ in thousands) Fair Value of Derivative Beginning balance at January 1, 2017 $ 167 Change in fair value of derivative liabilities (76 ) Ending balance at June 30, 2017 $ 91 Helocyte Convertible Notes at Fair Value Helocyte’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Helocyte’s convertible debt that is categorized within Level 3 of the fair value hierarchy as of June 30, 2017 is as follows: June 30, Risk-free interest rate 1.140% - 1.298 % Expected dividend yield - % Expected term in years 0.50 - 1.41 Expected volatility 59.1 % ($ in thousands) Helocyte Beginning balance at January 1, 2017 $ 4,487 Change in fair value of convertible notes 186 Ending balance at June 30, 2017 $ 4,673 At June 30, 2017, upon completion of Avenue’s IPO, Avenue’s convertible debt automatically converted into approximately 47,949 common shares of Avenue, at $4.02, a 33% discount to the IPO price, pursuant to the terms of the Convertible Note. As of June 30, 2017, Avenue’s obligation to its note holders was satisfied. ($ in thousands) Avenue Beginning balance at January 1, 2017 $ 200 Conversion into common shares (299 ) Change in fair value of convertible notes 99 Ending balance at June 30, 2017 $ - The following tables classify the fair value hierarchy of Fortress's financial instruments, exclusive of National's financial instruments, measured at fair value as of June 30, 2017 and December 31, 2016: Fair Value Measurement as of June 30, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 903 $ 903 Total $ - $ - $ 903 $ 903 Liabilities Warrant liabilities $ - $ - $ 91 $ 91 Helocyte Convertible Note, at fair value - - 4,673 4,673 Total $ - $ - $ 4,764 $ 4,764 Fair Value Measurement as of December 31, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,414 $ 1,414 Total $ - $ - $ 1,414 $ 1,414 Liabilities Contingently Issuable Warrants $ - $ - $ 302 $ 302 Warrant liabilities - - 179 179 Helocyte Convertible Note, at fair value - - 4,487 4,487 Avenue Convertible Note, at fair value - - 200 200 Total $ - $ - $ 5,168 $ 5,168 The following table shows the fair values hierarchy of National's financial instruments measured at fair value on a recurring basis on the Condensed Consolidated Balance Sheets as of March 31, 2017: Fair Value Measurement as of March 31, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 272 $ - $ - $ 272 Municipal bonds 2,928 - - 2,928 Restricted stock - 206 - 206 Total $ 3,200 $ 206 $ - $ 3,406 Liabilities National Securities sold, but not yet purchased at fair value Contingent consideration $ - $ - $ 630 $ 630 Corporate stocks 77 - - 77 Warrants - National - 8,190 8,190 Total $ 77 $ - $ 8,820 $ 8,897 Warrants issuable - National In accordance with the Company’s Merger Agreement with National, since less than 80% of National's issued and outstanding shares of common stock were tendered, National remains a publicly-traded company and National's stockholders post-tender offer received from National a five-year warrant per held share to purchase an additional share of National's common stock at $3.25 as a dividend to all holders of National's common stock. As National does not have the ability to settle the warrants with unregistered shares and maintenance of an effective registration statement may be considered outside of the Company’s control, net cash settlement of the warrants is assumed. The fair value of the 5.4 million National warrants represents 43.4% of the warrants issued to non-Fortress shareholders. These are being classified as a liability in the condensed consolidated statement of financial condition at June 30, 2017. Such valuation (using level 3 inputs) was determined by use of the Black-Scholes option pricing model using the following assumptions: March 31, Dividend yield - % Expected volatility 97.76 % Risk-free interest rate 1.93 % Life (in years) 4.5 ($ in thousands) National’s Beginning balance at December 31, 2016 $ 14,359 Change in fair value of derivative liability (6,169 ) Ending balance at March 31, 2017 $ 8,190 National listed the warrants on the Nasdaq Capital Market under the symbol “NHLDW” in February 2017. The table below provides a rollforward of the changes in fair value of Level 3 financial instruments for the six months ended June 30, 2017: ($ in thousands) Investment in Investment in Helocyte Avenue Warrants Warrant Total Balance at December 31, $ 1,164 $ 250 $ 4,487 $ 200 $ 14,661 $ 179 $ 20,941 Conversion into - - - (299 ) (750 ) (15 ) (1,064 ) Issuance of warrants - - - - (8,190 ) 8,190 - Change in fair value of investments (511 ) - - - - - (511 ) Change in fair value of convertible notes - - 186 99 - - 285 Change in fair value of derivative liabilities - - - - (5,721 ) (73 ) (5,794 ) Balance at June 30, 2017 $ 653 $ 250 $ 4,673 $ - $ - $ 8,281 $ 13,857 For the six months ended June 30, 2017, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

Licenses Acquired

Licenses Acquired	6 Months Ended
	Jun. 30, 2017
Licenses Acquired [Abstract]
Licenses Acquired	8. Licenses Acquired In accordance with ASC 730-10-25-1, Research and Development 1.8 3.1 For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2017 2016 2017 2016 Fortress $ 300 $ - $ 300 $ - Fortress Companies: Checkpoint - 2,060 400 2,060 Helocyte - - - 83 Mustang 1,500 - 2,075 - Caelum - - 219 - Cyprium - - 100 - Total $ 1,800 $ 2,060 $ 3,094 $ 2,143 Fortress: Effcon Laboratories, Inc. In September 2016, the Company entered into a development and license agreement with Effcon Laboratories, Inc. (“Effcon”) for the development of extended release formulation of Methozolamide. Pursuant to the Agreement, Fortress paid an upfront fee of $ 0.2 2.3 1.6 0.3 Checkpoint Therapeutics, Inc. Jubilant Biosys Limited In May 2016, Checkpoint entered into a license agreement with Jubilant Biosys Limited (“Jubilant”), whereby Checkpoint obtained an exclusive, worldwide license (the “Jubilant License”) to Jubilant’s family of patents covering compounds that inhibit BRD4, a member of the BET domain for cancer treatment, including CK-103. For the six months ended June 30, 2017, Checkpoint expensed a non-refundable milestone payment of $ 0.4 2.0 In connection with the Jubilant License, Checkpoint entered into a sublicense agreement with TG Therapeutics, Inc. (“TGTX”), a related party, to develop and commercialize the compounds licensed in the field of hematological malignancies, with Checkpoint retaining the right to develop and commercialize these compounds in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and the Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. For the three months ended June 30, 2017 and 2016, Checkpoint recognized $ 0.1 1.0 0.6 1.0 Dana-Farber Cancer Institute In connection with its license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX, a related party, to develop and commercialize the anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies, while Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and Fortress’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. For the three months ended June 30, 2017 and 2016, approximately $ 9,000 3,000 38,000 20,000 Mustang Bio, Inc. License Agreement with the City of Hope In March 2015, Mustang entered into an exclusive license agreement with City of Hope (“COH”) to acquire intellectual property rights pertaining to CAR-T (the “Original License”). On February 17, 2017, Mustang and COH amended and restated the Original License by entering into three separate exclusive license agreements, one relating to CD123 (the “CD123 License”), one relating to IL-13 (the “IL-13 License”) and one relating to the spacer technology (the “Spacer License”). The total potential consideration payable to COH by Mustang under the new license agreements, in equity or cash, did not, in the aggregate, change materially from the Original License. CD123 License Pursuant to the CD123 License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. COH is eligible to receive up to approximately $ 14.5 IL-13 License Pursuant to the IL-13 License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. COH is eligible to receive up to approximately $ 14.5 0.3 Spacer License Pursuant to the Spacer License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. No royalties are due if the Spacer technology is used in conjunction with a CD123 CAR or an IL-13 CAR, and royalty payments in the low single digits are due on net sales of licensed products if the Spacer technology is used in conjunction with other intellectual property. Mustang is obligated to pay COH a percentage (in the mid-thirties) of certain revenues received in connection with a sublicense. In addition, equity grants made under the Original License were acknowledged, and the anti-dilution provisions of the Original License were carried forward. IV/ICV Agreement On February 17, 2017, Mustang entered into an exclusive license agreement (the “IV/ICV Agreement”) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV Agreement, Mustang paid COH an upfront fee of $ 0.1 0.1 HER2 Technology License On May 31, 2017, Mustang entered into an exclusive license agreement with the COH for the use of human epidermal growth factor receptor 2 (HER2) CAR T technology (HER2 Technology), which will initially be applied in the treatment of glioblastoma multiforme. Pursuant to the Agreement, Mustang paid an upfront fee of $ 0.6 50,000 14.9 CS1 Technology License On May 31, 2017, Mustang entered into an exclusive license agreement with the COH for the use of CS1 specific CAR T technology (CS1 Technology) to be directed against multiple myeloma. Pursuant to the Agreement, Mustang paid an upfront fee of $ 0.6 50,000 14.9 PSCA Technology License On May 31, 2017, Mustang entered into an exclusive license agreement with the COH for the use of prostate stem cell antigen (PSCA) CAR T technology (PSCA Technology) to be used in the treatment of prostate cancer. Pursuant to the Agreement, Mustang paid an upfront fee of $ 0.3 50,000 14.9 License with University of California On March 17, 2017, Mustang entered into an exclusive license agreement with the Regents of the University of California (“UCLA License”) to acquire intellectual property rights in patent applications related to the engineered anti-prostate stem cell antigen antibodies for cancer targeting and detection. Pursuant to the UCLA Agreement, Mustang paid UCLA an upfront fee of $ 0.2 Caelum Biosciences, Inc. License Agreement with Columbia University In January 2017, Caelum entered into an exclusive license agreement with Columbia University (“Columbia”) to secure worldwide license rights to CAEL-101 (11-1F4), a chimeric fibril-reactive monoclonal antibody (mAb) being evaluated in a Phase 1a/1b study for the treatment of amyloid light chain (“AL”) amyloidosis. This transaction was accounted for as an asset acquisition pursuant to ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, . 0.2 1,050,000 10 29,000 0.028 5.5 Cyprium Therapeutics, Inc. License Agreement with the Eunice Kennedy Shriver In March 2017, Cyprium and the Eunice Kennedy Shriver Business Combinations (Topic 805): Clarifying the Definition of a Business, . 0.1

Sponsored Research Agreements

Sponsored Research Agreements	6 Months Ended
	Jun. 30, 2017
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure	9. Sponsored Research Agreements Checkpoint Therapeutics, Inc. NeuPharma, Inc. Sponsored Research Agreement In connection with its license agreement with NeuPharma, Inc. (“NeuPharma”), Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities. Effective January 11, 2016, TGTX, a related party, agreed to assume all costs associated with this Sponsored Research Agreement and paid Checkpoint for all amounts previously paid by the Company. For the three months ended June 30, 2017 and 2016, approximately $ 0.2 0.2 For the six months ended June 30, 2017 and 2016, approximately $ 0.4 0.5 Helocyte, Inc. PepVax and Triplex Clinical Research and Support Agreements In March 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its PepVax immunotherapy for CMV control in allogeneic stem cell transplant recipients (“PepVax Research Agreement”). The Phase 2 study is additionally supported by grants from the National Institutes of Health/National Cancer Institute (“NCI”). In February 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its Triplex immunotherapy for CMV control in allogeneic stem cell transplant recipients (“Triplex Research Agreement”). For the three months ended June 30, 2017 and 2016, Helocyte incurred expense of $ 0.5 1.0 1.0 0.2 1.0 Pentamer Sponsored Research Agreement On May 1, 2017, Helocyte and COH entered in a Sponsored Research Agreement for preclinical studies in connection with the development of Pentatmer. In June 2017, Helocyte made an upfront payment of $ 1.5 12,000 Mustang Bio, Inc. In connection with Mustang’s license with COH for the development of CAR-T, Mustang entered into a Sponsored Research Agreement in which Mustang will fund continued research in the amount of $ 2.0 0.5 0.5 1.0 1.0 CD 123 Clinical Research Support Agreement On February 17, 2017, Mustang entered into a Clinical Research Support Agreement for CD123. Pursuant to the terms of this agreement Mustang made an upfront payment of approximately $ 20,000 0.1 0.2 22,000 0.6 IL - 13 Clinical Research Support Agreement Also on February 17, 2017, Mustang entered into a Clinical Research Support Agreement for IL-13. Pursuant to the terms of this agreement Mustang made an upfront payment of approximately $ 10,000 0.1 0.2 11,000 1.0

Intangibles, net

Intangibles, net	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, net	10. Intangibles, net Journey Medical Corporation Pursuant to the terms of Journey’s license agreements for its branded products, Journey made upfront payments totaling $ 1.6 0.1 21,000 0.3 21,000

Debt and Interest

Debt and Interest	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt and Interest	11. Debt and Interest Debt June 30, December 31, ($ in thousands) 2017 2016 Interest rate Maturity IDB Note $ 14,929 $ 14,929 2.25 % Feb - 2018 NSC Note 3,608 3,608 8.00 % Sep - 2018 2017 Subordinated Note Financing 3,254 - 8.00 % March - 2020 2017 Subordinated Note Financing 13,893 - 8.00 % May - 2020 2017 Subordinated Note Financing 1,820 - 8.00 % June - 2020 Opus Credit Facility 9,500 7,000 12.00 % Sep - 2018 Helocyte Convertible Note, at fair value 1,076 1,031 5.00% - 8.00% December 2017 Helocyte Convertible Note, at fair value 2,135 2,051 5.00% - 8.00% March - 2018 Helocyte Convertible Note, at fair value 1,032 991 5.00% - 8.00% April - 2018 Helocyte Convertible Note, at fair value 430 414 5.00% - 8.00% May - 2018 Avenue Convertible Note, at fair value - 200 5.00% - 8.00% June - 2018 Total notes payable 51,677 30,224 Less: Discount on notes payable 4,723 2,009 Total notes payable $ 46,954 $ 28,215 IDB Note On February 13, 2014, the Company executed a secured promissory note in favor of Israel Discount Bank of New York (“IDB”) in the amount of $ 15.0 14.9 15.0 2017 Subordinated Note Financing On March 31, 2017, the Company entered into Note Purchase Agreements (the “Purchase Agreements”) with NAM Biotech Fund II, LLC I (“NAM Biotech Fund”) and NAM Special Situations Fund I QP, LLC (“NAM Special Situations Fund”), both of which are accredited investors, and sold subordinated promissory notes (the “Notes”) of the Company (the “2017 Subordinated Note Financing”) in the aggregate principal amount of $ 3.25 8 7 Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion. 40.0 50.0 National Securities Corporation (“NSC”), a subsidiary of National and a related party, (see Note 17), pursuant to a Placement Agency Agreement entered into between the Company, NAM Biotech Fund and NSC (the “NAM Placement Agency Agreement”) and a Placement Agency Agreement entered into between the Company, NAM Special Situations Fund and NSC (together with the NAM Placement Agency Agreement, the “Placement Agency Agreements”) acts as placement agent in the 2017 Subordinated Note Financing. Pursuant to the terms of the Placement Agency Agreements, NSC receives (in addition to reimbursement of certain expenses) an aggregate cash fee equal to 10 10 In connection with the initial closing of the 2017 Subordinated Note Financing, NSC received a cash fee of $ 325,400 87,946 0.2 On May 1, 2017, the Company held a second closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 8.6 0.9 234,438 3.65 On May 31, 2017, the Company held a third closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 5.3 0.5 147,806 3.61 On June 30, 2017, the Company held a fourth closing of the 2017 Subordinated Note Financing and received gross proceeds of $ 1.8 0.2 38,315 4.75 Opus Credit Facility As of June 30, 2017, the Company had $ 9.5 1.6 Interest Expense For the Three Months Ended June 30, For the Three Months Ended June 30, ($ in thousands) 2017 2016 2017 2016 IDB Note Interest $ 87 $ 79 $ 169 $ 159 Amortization of fees - - - 1 Total IDB Note 87 79 169 160 NSC Debt Interest 84 144 155 311 Amortization of fees 40 54 73 422 Total NSC Debt 124 198 228 733 NHLD Debt Interest 406 - 406 - Amortization of fees 175 - 175 - Total NHLD Debt 581 - 581 - Opus Credit Facility Interest 276 - 508 - Amortization of fees 241 - 454 - Total Opus Note 517 - 962 - LOC Fees Interest 7 3 15 7 Total LOC 7 3 15 7 Helocyte Convertible Note Interest 57 - 111 - Financing fee - 249 1 249 Total Helocyte Convertible Note 57 249 112 249 Avenue Convertible Note Interest 5 - 5 - Financing fee - - 3 - Total Helocyte Convertible Note 5 - 8 - D&O Insurance Interest 2 - 3 - Total D&O Insurance 2 - 3 - Total Interest Expense and Financing Fee $ 1,380 $ 529 $ 2,078 $ 1,149

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	6 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	12. Accrued Expenses and Other Long-Term Liabilities June 30, December 31, ($ in thousands) 2017 2016 Accrued expenses: Professional fees $ 1,748 $ 1,253 Salaries, bonuses and related benefits 2,295 2,846 Accrued Severance - 53 Ovamed manufacturing rights - short term component - 900 Research and development 2,914 394 Dr. Falk Pharma milestone 2,852 2,634 Other 2,564 2,002 Total accrued expenses $ 12,373 $ 10,082 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 5,026 5,014 Total other long-term liabilities $ 5,026 $ 5,014 March 31, 2017 Legal $ 766 Audit 287 Telecommunications 187 Data Services 348 Regulatory 1,061 Settlements 1,131 Deferred rent 630 Contingent consideration payable 121 Other 2,592 Total $ 7,123

Non-Controlling Interests

Non-Controlling Interests	6 Months Ended
	Jun. 30, 2017
Noncontrolling Interest [Abstract]
Non-Controlling Interests	13. Non-Controlling Interests Non-controlling interests in consolidated entities, as recorded on the Condensed Consolidated Balance Sheets are as follows: As of June 30, 2017 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation Caelum National Holdings Total NCI equity share $ 3,089 $ (236) $ 47,009 $ 22,026 $ (570) $ (1,677) $ (151) $ (3) $ 17,022 $ 86,509 Net loss attributed to non-controlling interests (314) (7) (5,027) (6,707) (48) (599) (83) (251) 4,872 (8,164) Non-controlling interests in consolidated entities $ 2,775 $ (243) $ 41,982 $ 15,319 $ (618) $ (2,276) $ (234) $ (254) $ 21,894 $ 78,345 As of December 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation National Holdings Total NCI equity share $ (494) $ (217) $ 12,376 $ 32,160 $ (192) $ (612) $ 4 $ 17,643 $ 60,668 Net loss attributed to non-controlling interests (349) (19) (1,805) (11,733) (355) (1,155) (158) (621) (16,195) Non-controlling interests in consolidated entities $ (843) $ (236) $ 10,571 $ 20,427 $ (547) $ (1,767) $ (154) $ 17,022 $ 44,473 The components of non-controlling interests in loss of consolidated entities, as recorded on the Condensed Consolidated Statement of Operations are as follows: For the three months ended June 30, 2017 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Cellvation Caelum National Holdings Total Non-controlling interests in loss of consolidated entities $ (246) $ (3) $ (3,353) $ (3,972) $ 20 $ (276) $ (30) $ (106) $ 2,382 $ 5,584 Non-controlling ownership (3) 10.2 % 13.0 % 52.0 % 62.4 % 7.0 % 20.0 % 22.0 % 25.5 % 43.4 For the three months ended June 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (76) $ (5) $ (89) $ (3,476) $ (108) $ (157) $ (3,911) Non-controlling ownership (3) 11.5 % 13.0 % 10.0 % 64.3 % 8.1 % 20.4 % For the six months ended June 30, 2017 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Cellvation Caelum National Holdings Total Non-controlling interests in loss of consolidated entities $ (314) $ (7) $ (5,027) $ (6,707) $ (48) $ (599) $ (83) $ (251) $ 4,872 $ (8,164) Non-controlling ownership (3) 10.2 % 13.0 % 60.8 % 61.6 % 7.3 % 20.0 % 22.0 % 25.5 % 43.4 % For the six months ended June 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (184) $ (10) $ (159) $ (7,513) $ (229) $ (254) $ (8,349) Non-controlling ownership (3) 11.5 % 13.0 % 10.0 % 64.3 %(1) 8.1 % 20.4 % (1) - Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights. (2) - Mustang and Avenue are consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Mustang’s Class A preferred shares which provide super-majority voting rights (3) - Represents a weighted average of ownership during the periods presented.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Loss Per Common Share	14. Net Loss per Common Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company’s common stock equivalents, including unvested restricted stock, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same. For the Six Months Ended June 30, 2017 2016 Warrants to purchase Common Stock 603,316 515,068 Opus warrants to purchase Common Stock 1,880,000 - Options to purchase Common Stock 1,101,193 1,754,365 Unvested Restricted Stock 9,864,417 8,705,137 Unvested Restricted Stock Units 1,258,372 1,374,083 Total 14,707,298 12,348,653

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	15. Stockholders’ Equity Stock-based Compensation excluding National As of June 30, 2017, the Company had four equity compensation plans: the Fortress Biotech, Inc. 2007 Stock Incentive Plan, the Fortress Biotech, Inc. 2013 Stock Incentive Plan, as amended, the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan and the Fortress Biotech, Inc. Long Term Incentive Plan. For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2017 2016 2017 2016 Employee awards $ 1,690 $ 1,969 $ 3,520 $ 3,553 Non-employee awards 23 3 36 6 Fortress Companies (1) 3,094 1,051 4,180 2,330 Total stock-based compensation expense $ 4,807 $ 3,023 $ 7,736 $ 5,889 (1) Consists of approximately $ 19,000 2.4 73,000 34,000 6,000 183,000 24,000 3.4 119,000 81,000 14,000 183,000 Consists of approximately $ 9,000 0.8 147,000 93,000 18,000 1.9 328,000 93,000 For the three months ended June 30, 2017 and 2016, approximately $ 2.4 1.1 2.2 1.9 For the six months ended June 30, 2017 and 2016, approximately $ 3.2 2.4 4.3 3.5 Weighted average Weighted Total weighted remaining average average intrinsic contractual life Number of shares exercise price value (years) Options vested and expected to vest at December 31, 2016 1,130,501 $ 3.73 $ 602,451 4.93 Exercised (20,000) 1.37 67,600 - Options vested and expected to vest at June 30, 2017 1,110,501 $ 3.78 $ 1,826,461 4.46 Options vested and exercisable 1,085,501 $ 3.75 $ 1,826,461 4.43 As of June 30, 2017, and 2016, Fortress had unrecognized stock-based compensation expense related to options of nil and $ 33,000 0.03 2.8 0.2 0.2 Weighted average Number of shares grant price Unvested balance at December 31, 2016 10,094,095 $ 2.49 Restricted stock granted 1,325,396 2.70 Restricted stock vested (213,333) 2.75 Restricted stock units granted 197,500 3.74 Restricted stock units forfeited (15,000) 2.98 Restricted stock units vested (138,750) 3.47 Unvested balance at June 30, 2017 11,249,908 $ 2.52 As of June 30, 2017 and 2016, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $ 2.7 6.4 2.3 2.4 Employee Stock Purchase Plan Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85 As of June 30, 2017, 199,995 5 40,000 30,000 75,000 56,000 Warrants Weighted average Total weighted remaining Weighted average average intrinsic contractual life Number of shares exercise price value (years) Outstanding as of December 31, 2016 2,263,453 $ 3.62 $ 79,800 4.74 Granted 608,505 3.61 518,724 4.86 Forfeited (123,007) 8.39 - - Outstanding as of June 30, 2017 2,748,951 $ 3.40 $ 940,203 3.77 Exercisable as of June 30, 2017 768,951 $ 4.37 $ 765,203 3.75 Long-Term Incentive Program (“LTIP”) On January 1, 2017 and 2016, the Compensation Committee granted 552,698 510,434 100.0 1.5 1.4 0.2 0.1 0.3 0.1 Fortress Companies Checkpoint Therapeutics, Inc. Checkpoint has a long-term incentive plan under which it has issued grants to both employees and non-employees. For the three months ended June 30, 2017 and 2016, Checkpoint re-measured its non-employee grant and recorded expense of approximately $ 1.9 0.5 2.4 1.2 Certain Checkpoint employees and directors also have been awarded restricted stock under Checkpoint’s 2015 Incentive Plan. Checkpoint recorded stock-based compensation expense of $ 0.4 0.4 1.0 0.7 Avenue Therapeutics, Inc. In connection with stock grants made to both employees and non-employees, Avenue for the three months ended June 30, 2017 and 2016, recorded approximately $ 10 4 10 4 12,000 9 12 9 Journey Medical Corporation During the six months ended June 30, 2017, JMC granted option awards to numerous sales employees exercisable for 320,000 The fair value of stock options granted was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, and expected dividend yield. The stock price was determined utilizing a discounted cash flow model to determine the weighted market value of invested capital. JMC does not expect to pay dividends in the foreseeable future. As a result, the expected dividend yield is 0 June 30, 2017 Risk-free interest rate 1.14% - 2.25 % Expected dividend yield - % Expected term in years 5.00 - 6.98 Expected volatility 95.25% - 105.95 % Mustang Bio, Inc. The employment agreement grants Dr. Litchman an option to purchase 1,041,675 5.73 On April 7, 2017, Mustang granted 200,000 The fair value of stock options granted was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, expected dividend yield, and a stock price of $5.73. Mustang does not expect to pay dividends in the foreseeable future. As a result, the expected dividend yield is 0%. June 30, Risk-free interest rate 2.38 % Expected dividend yield - % Expected term in years 5.5 to 10.0 Expected volatility 77.3 % Stock Options Weighted Average Weighted Average Remaining Contractual Nonvested at December 31, 2016 - $ - - Options granted 1,241,675 $ 5.73 9.81 Options outstanding 1,241,675 5.73 9.81 Options vested and exercisable at June 30, 2017 - $ - - As of June 30, 2017, Mustang had unrecognized stock-based compensation expense related to options of $ 2.1 9.81 During the three and six months ended June 30, 2017, stock-based compensation associated with the amortization of stock option expense was approximately $ 64,000 0.1 0.1 0.3 Helocyte, Inc. For the three months ended June 30, 2017 and 2016, Helocyte re-measured its non-employee grants and recorded expense of approximately $ 25,000 68,000 For the three months ended June 30, 2017 and 2016, Helocyte recorded approximately $ 8,000 25,000 For the six months ended June 30, 2017 and 2016, Helocyte re-measured its non-employee grants and recorded expense of approximately $ 62,000 68,000 For the six months ended June 30, 2017 and 2016, Helocyte recorded approximately $ 18,000 25,000 Cellvation, Inc. For the three and six months ended June 30, 2017, Cellvation recorded expenses for non-employee grants of approximately $ 2,000 5,000 For the three and six months ended June 30, 2017, Cellvation recorded approximately $ 4,000 8,000 Capital Raises Avenue On June 30, 2017, Avenue completed an initial public offering (“IPO”) of its common stock, which resulted in the issuance of 6,325,000 825,000 6.00 34.5 3-For-1 In conjunction with the closing of the IPO, Avenue issued warrants in connection with its NSC Debt and its Convertible Notes. Mustang In September 2016, Mustang entered into a Placement Agent Agreement with NSC relating to Mustang’s offering of shares of common stock in a private placement. Pursuant to the Placement Agent Agreement, Mustang agreed to pay NSC a cash fee of 10.0 10,000 2,500 8.50 65,000 On January 31, 2017, Mustang held a sixth closing of its private placement for gross proceeds of $ 55.5 8,536,774 2,134,193 5.5 853,677 10 On March 31, 2017, Mustang closed an additional private placement with substantially similar terms as the offering described above resulting in gross proceeds of $0.4 million, before expenses. Mustang issued 64,000 16,000 42,000 10 Pursuant to the Founders Agreement (see Note 17), Mustang issued 215,019 2.5 1.2 As of June 30, 2017, the Company determined that the warrants still did not meet the definition of a derivative and continued to qualify for equity recognition.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Indemnification In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. Pursuant to agreements with clinical trial sites, the Company provides indemnification to such sites in certain conditions. Legal Proceedings - Fortress In the ordinary course of business, the Company and its subsidiaries may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages. Litigation and Regulatory Matters - National National and its subsidiaries are defendants or respondents in various pending and threatened arbitrations, administrative proceedings and lawsuits seeking compensatory damages. Several cases have no stated alleged damages. Claim amounts are infrequently indicative of the actual amounts National will be liable for, if any. Further, National has a history of collecting amounts awarded in these types of matters from its registered representatives that are still affiliated, as well as from those that are no longer affiliated. Many of these claimants also seek, in addition to compensatory damages, punitive or treble damages, and all seek interest, costs and fees. These matters arise in the normal course of business. National intends to vigorously defend itself in these actions, and the ultimate outcome of these matters cannot be determined at this time. Liabilities for potential losses from complaints, legal actions, government investigations and proceedings are established where National believes that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In making these decisions, management bases its judgments on its knowledge of the situations, consultations with legal counsel and its historical experience in resolving similar matters. In many lawsuits, arbitrations and regulatory proceedings, it is not possible to determine whether a liability has been incurred or to estimate the amount of that liability until the matter is close to resolution. However, accruals are reviewed regularly and are adjusted to reflect National’s estimates of the impact of developments, rulings, advice of counsel and any other information pertinent to a particular matter. Because of the inherent difficulty in predicting the ultimate outcome of legal and regulatory actions, management cannot predict with certainty the eventual loss or range of loss related to such matters.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Note	17. Related Party Transactions Shared Services Agreement with TGTX TGTX and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is Executive Chairman and Interim Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the three months ended June 30, 2017 and 2016, the Company invoiced TGTX $ 0.4 0.2 0.6 0.3 . At June 30, 2017, the amount receivable from TGTX approximated $ 0.3 Desk Space Agreements with TGTX and OPPM In connection with the Company’s Desk Space Agreements with TGTX and Opus Point Partners Management, LLC (“OPPM”), as of June 30, 2017, the Company had paid $ 1.2 0.1 0.5 0.2 89,000 20,000 At June 30, 2017, the amount due from TGTX approximated $ 0.2 0.2 Opus Credit Facility In September 2016, the Company and Opus Point Health Innovations Fund (“OPHIF”) entered into a Credit Facility Agreement (the “Opus Credit Facility”). Fortress’s Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) and Fortress’s Executive Vice President, Strategic Development (Michael Weiss), are Co-Portfolio Managers and Partners of OPPM, an affiliate of OPHIF. As such, all of the disinterested directors of Fortress’s board of directors approved the terms of the Opus Credit Facility and related agreements (see Note 11). 2017 Subordinated Note Financing On March 17, 2017, the Company and NSC, a subsidiary of National, of which the Company owns 56.6 10 10 For the three and six months ended June 30, 2017, NSC earned a placement agent fee of $ 1.6 1.9 508,505 3.61 4.75 Avenue IPO On June 30, 2017, Avenue completed an IPO in which NSC acted as co-manager and earned fees and commissions of approximately 2.3 Founders Agreements The Company has entered into Founders Agreements and, in some cases, Exchange Agreements with certain of its subsidiaries as described in the Company’s Form 10-K for the year ended December 31, 2016, filed with the SEC on March 16, 2017. PIK Dividend as a % of fully diluted outstanding Class of Stock Fortress Company Effective Date (1) capitalization Issued Helocyte March 20, 2015 2.5 % Common Stock Avenue February 17, 2015 2.5 % Common Stock Mustang March 13, 2015 2.5 % Common Stock Checkpoint March 17, 2015 0.0 % (2) Common Stock Cellvation October 31, 2016 2.5 % Common Stock Caelum January 1, 2017 2.5 % Common Stock Cyprium March 13, 2017 2.5 % Common Stock (1) - Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement. (2) - Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5 On June 30, 2017, pursuant to the Founders’ Agreement, Avenue, in connection with its IPO, issued to Fortress approximately 158,000 2.5 Management Services Agreements The Company has entered in Management Services Agreements (the “MSAs”) with certain of its subsidiaries as described in the Company’s Form 10-K for the year ended December 31, 2016, filed with the SEC on March 16, 2017. ($ in thousands) Fortress Annual MSA Fee Company Effective Date R&D G&A (Income)/Expense Helocyte March 20, 2015 $ 250 $ 250 $ 500 Avenue February 17, 2015 250 250 500 Mustang March 13, 2015 250 250 500 Checkpoint March 17, 2015 250 250 500 Cellvation October 31, 2016 250 250 500 Caelum January 1, 2017 250 250 500 Cyprium March 13, 2017 250 250 500 Fortress (1,750) (1,750) (3,500) Consolidated (Income)/Expense $ - $ - $ - Chord Advisors, LLC In May 2015, the Company entered into a full-service consulting agreement with Chord Advisors, LLC (“Chord”) to provide advisory accounting services. Under the terms of the agreement, the Company pays Chord $ 10,000 5,000 7,500 28,000 48,000 National As of June 30, 2017, the Company owns approximately 56.6 Additionally, the Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM which owns approximately 4.6

Net Capital Requirements of Bro

Net Capital Requirements of Broker-Dealer Subsidiaries	6 Months Ended
	Jun. 30, 2017
Brokers and Dealers [Abstract]
Net Capital Requirements of Broker-Dealer Subsidiaries	18. Net Capital Requirements of Broker-Dealer Subsidiaries NSC is subject to the SEC's Uniform Net Capital Rule (Rule 15c3-1) (the "Rule"), which, among other things, requires the maintenance of minimum net capital. At March 31, 2017, National Securities had net capital of $ 7,924,058 7,674,058 250,000 vFinance Investments, Inc. (vFinance Investments) is also subject to the Rule, which, among other things, requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 1 2,167,442 1,167,442 1,000,000 0.8 1 Advances, dividend payments and other equity withdrawals from the Company's broker-dealer subsidiaries are restricted by the regulations of the SEC, and other regulatory agencies. These regulatory restrictions may limit the amounts that a subsidiary may dividend or advance to the Company.

Off Balance Sheet Risk and Conc

Off Balance Sheet Risk and Concentrations of Credit Risk	6 Months Ended
	Jun. 30, 2017
Risks and Uncertainties [Abstract]
Off Balance Sheet Risk and Concentrations of Credit Risk	19. Off Balance Sheet Risk and Concentrations of Credit Risk National is engaged in trading and providing a broad range of securities brokerage and investment services to a diverse group of retail and institutional clientele, as well as corporate finance and investment banking services to corporations and businesses. Counterparties to National’s business activities include broker-dealers and clearing organizations, banks and other financial institutions. National uses clearing brokers to process transactions and maintain customer accounts for National on a fee basis. National permits the clearing firms to extend credit to its clientele secured by cash and securities in the client’s account. National’s exposure to credit risk associated with the non-performance by its customers and counterparties in fulfilling their contractual obligations can be directly impacted by volatile or illiquid trading markets, which may impair the ability of customers and counterparties to satisfy their obligations to National. National has agreed to indemnify the clearing brokers for losses they incur while extending credit to National’s clients. It is National’s policy to review, as necessary, the credit standing of its customers and counterparties. Amounts due from customers that are considered uncollectible by the clearing broker are charged back to National by the clearing broker when such amounts become determinable. Upon notification of a charge back, such amounts, in total or in part, are then either (i) collected from the customers, (ii) charged to the broker initiating the transaction and/or (iii) charged to operations, based on the particular facts and circumstances. National maintains cash in bank deposits, which, at times, may exceed federally insured limits. National has not experienced and does not expect to experience losses on such accounts. A short sale involves the sale of a security that is not owned in the expectation of purchasing the same security (or a security exchangeable) at a later date at a lower price. A short sale involves the risk of a theoretically unlimited increase in the market price of the security that would result in a theoretically unlimited loss.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Information	20. Segment Information The Company operates in three reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The accounting policies of the Company’s segments are the same as those described in Note 2. Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold Pharmaceutical and Dermatology Biotechnology ($ in thousands) Products Product Three Months Ended June 30, 2017 Sales Development National Consolidated Net Revenue $ 4,054 $ 350 $ 46,293 $ 50,697 Direct cost of goods (878) - - (878) Sales and marketing costs (2,610) - - (2,610) Research and development - (13,483) - (13,483) General and administrative (293) (8,231) - (8,524) National Expenses - - (48,395) (48,395) Segment loss from operations $ 273 $ (21,364) $ (2,102) $ (23,193) Segment assets $ 5,447 $ 167,787 $ 76,612 $ 249,846 Dermatology Pharmaceutical and Products Biotechnology Product Three Months Ended June 30, 2016 Sales Development Consolidated Net Revenue $ 982 $ 1,248 $ 2,230 Direct cost of goods (324) - (324) Sales and marketing costs (1,998) - (1,998) Research and development - (8,407) (8,407) General and administrative - (6,637) (6,637) Segment loss from operations $ (1,340) $ (13,796) $ (15,136) Segment assets $ 3,058 $ 95,004 $ 98,062 Pharmaceutical and Dermatology Biotechnology ($ in thousands) Products Product Six Months Ended June 30, 2017 Sales Development National Consolidated Net Revenue $ 6,139 $ 1,043 $ 88,197 $ 95,379 Direct cost of goods (1,347) - - (1,347) Sales and marketing costs (4,877) - - (4,877) Research and development - (21,887) - (21,887) General and administrative (612) (15,897) - (16,509) National Expenses - - (91,529) (91,529) Segment loss from operations $ (697) $ (36,741) $ (3,332) $ (40,770) Segment assets $ 5,447 $ 167,787 $ 76,612 $ 249,846 Dermatology Pharmaceutical and Products Biotechnology Six Months Ended June 30, 2016 Sales Product Development Consolidated Net Revenue $ 1,364 $ 1,526 $ 2,890 Direct cost of goods (324) - (324) Sales and marketing costs (3,884) - (3,884) Research and development - (16,243) (16,243) General and administrative - (12,666) (12,666) Segment loss from operations $ (2,844) $ (27,383) $ (30,227) Segment assets $ 3,058 $ 95,004 $ 98,062 Significant Customers For the three months ended June 30, 2017, two of the Company’s customers each accounted for more than 10.0% of its total gross revenue in the amount of $ 4.2 2.2 5.3 3.8 For the three months ended June 30, 2016, three of our customers accounted for more than 10.0% of our total revenue in the amount of $ 0.3 0.3 0.3 0.6 0.3 0.3 At June 30, 2017, two of the Company’s customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 2.1 0.7 At December 31, 2016, two of the Company’s customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 1.1 0.5 Net Revenue from Pharmaceutical and Biotechnology Product Development represents collaboration revenue from TGTX in connection with Checkpoint, which is classified as related party revenue.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events NSC Note On July 5, 2017, the Company and Avenue repaid their respective outstanding NSC Notes totaling $ 3.6 3.0 0.6 Fortress Note Payable - Avenue On July 25, 2017, Avenue repaid its Fortress Note in the amount of $ 3.8

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year for each of the Company, Avenue, Checkpoint, Mustang and National. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2017, from which the Company derived the balance sheet data at December 31, 2016, as well as National’s Form 10-K, filed with SEC on December 29, 2016 and their Form 10-Q, filed with the SEC on May 15, 2017, Checkpoint’s Forms 10-K and 10-K/A, filed with the SEC on March 17, 2017 and March 21, 2017, respectively, Mustang’s Form 10-K, filed with the SEC on March 31, 2017, and Avenue’s Form 10-12G/A, filed with the SEC on March 27, 2017. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: NHLD, Innmune Limited, Coronado SO, Cyprium, Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang, Helocyte, Cellvation and Caelum. All intercompany balances and transactions have been eliminated. The National assets acquired and liabilities assumed and revenues and expenses are reported on a one quarter lag. Therefore, the National assets acquired and liabilities assumed included in these consolidated financial statements as of June 30, 2017 are actually the assets and liabilities as of March 31, 2017 and the revenues and expenses included in these consolidated financial statements for the quarter ending June 30, 2017 are actually the revenues and expenses for the quarter ending March 31, 2017. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Significant Accounting Policies	There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Form 10-K filed with the SEC on March 16, 2017, with the exception of the policies listed below.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at June 30, 2017 and at December 31, 2016 consisted of cash, money market funds and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities. Items with maturities greater than 90 days but less than one year at the time of acquisition are considered short-term investments.
Investments at Fair Value	Short-term Investments – Held to Maturity The company classifies its certificates of deposit as held to maturity in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) 320, Investments – Debt and Equity Securities 20.0 20.0 250,000 Investments consist of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the Company’s certificates of deposit approximated fair value.
Recently Issued Accounting Standards	Recently Adopted Accounting Pronouncements In March 2016, the FASB issued Accounting Standards Update ("ASU") 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception

National Holdings Corporation29

National Holdings Corporation Acquisition – Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	Amortization is calculated using the straight-line and accelerated methods over the following estimated useful lives: Useful life Trademark 10 years Customer lists 10 years
Schedule of Finite-Lived Intangible Assets	The carrying amount related to acquired intangible assets as of June 30, 2017 are as follows ($ in thousands): Intangible assets at December 31, 2016 $ 15,991 Amortization expense (819) Intangible assets at June 30, 2017 $ 15,172
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The future amortization of these intangible assets is as follows ($ in thousands): Total Six Months Ended December 31, 2017 $ 831 Year Ended December 31, 2018 1,649 Year Ended December 31, 2019 1,649 Year Ended December 31, 2020 1,654 Year Ended December 31, 2021 1,649 Thereafter 7,740 Total $ 15,172

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	Fortress's property and equipment, exclusive of National's property and equipment, consisted of the following ($ in thousands): Estimated Useful June 30, December 31, Lives (in years) 2017 2016 Computer equipment 3 $ 517 $ 440 Furniture and fixtures 5 931 821 Leasehold improvements Various 5,351 5,396 Total property and equipment 6,799 6,657 Less: accumulated depreciation (801) (445) Property and equipment, net $ 5,998 $ 6,212
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: For the Three Months Ended June 30, For the Three Months Ended June 30, ($ in thousands) 2017 2016 2017 2016 IDB Note Interest $ 87 $ 79 $ 169 $ 159 Amortization of fees - - - 1 Total IDB Note 87 79 169 160 NSC Debt Interest 84 144 155 311 Amortization of fees 40 54 73 422 Total NSC Debt 124 198 228 733 NHLD Debt Interest 406 - 406 - Amortization of fees 175 - 175 - Total NHLD Debt 581 - 581 - Opus Credit Facility Interest 276 - 508 - Amortization of fees 241 - 454 - Total Opus Note 517 - 962 - LOC Fees Interest 7 3 15 7 Total LOC 7 3 15 7 Helocyte Convertible Note Interest 57 - 111 - Financing fee - 249 1 249 Total Helocyte Convertible Note 57 249 112 249 Avenue Convertible Note Interest 5 - 5 - Financing fee - - 3 - Total Helocyte Convertible Note 5 - 8 - D&O Insurance Interest 2 - 3 - Total D&O Insurance 2 - 3 - Total Interest Expense and Financing Fee $ 1,380 $ 529 $ 2,078 $ 1,149
National Holdings Corporation [Member]
Property, Plant and Equipment [Line Items]
Schedule Of Interest Expenses For Debt Arrangements	National's property and equipment as of March 31, 2017 consisted of the following ($ in thousands): March 31, Estimated Useful 2017 Lives (in years) Equipment $ 861 5 Furniture and fixtures 82 5 Leasehold improvements 335 Lesser of useful life or term of lease Capital leases (primarily composed of computer equipment) 276 5 Total property and equipment 1,554 Less: accumulated depreciation (223) Property and equipment, net $ 1,331

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Avenue’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2017 $ 302 Conversion into common shares (750) Change in fair value 448 Ending balance at June 30, 2017 $ -
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables classify the fair value hierarchy of Fortress's financial instruments, exclusive of National's financial instruments, measured at fair value as of June 30, 2017 and December 31, 2016: Fair Value Measurement as of June 30, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 903 $ 903 Total $ - $ - $ 903 $ 903 Liabilities Warrant liabilities $ - $ - $ 91 $ 91 Helocyte Convertible Note, at fair value - - 4,673 4,673 Total $ - $ - $ 4,764 $ 4,764 Fair Value Measurement as of December 31, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,414 $ 1,414 Total $ - $ - $ 1,414 $ 1,414 Liabilities Contingently Issuable Warrants $ - $ - $ 302 $ 302 Warrant liabilities - - 179 179 Helocyte Convertible Note, at fair value - - 4,487 4,487 Avenue Convertible Note, at fair value - - 200 200 Total $ - $ - $ 5,168 $ 5,168
Schedule of changes in fair value of financial instruments	The table below provides a rollforward of the changes in fair value of Level 3 financial instruments for the six months ended June 30, 2017: Helocyte Avenue Convertible Convertible Warrants Investment in Investment in Note, at fair Note, at fair issued and Warrant ($ in thousands) Origo laser device value value issuable liabilities Total Balance at December 31, 2016 $ 1,164 $ 250 $ 4,487 $ 200 $ 14,661 $ 179 $ 20,941 Conversion into common shares - - - (299) (750) (15) (1,064) Issuance of warrants - - - - (8,190) 8,190 - Change in fair value of investments (511) - - - - - (511) Change in fair value of convertible notes - - 186 99 - - 285 Change in fair value of derivative liabilities - - - - (5,721) (73) (5,794) Balance at June 30, 2017 $ 653 $ 250 $ 4,673 $ - $ - $ 8,281 $ 13,857
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	March 31, 2017 Dividend yield - % Expected volatility 97.76 % Risk-free interest rate 1.93 % Life (in years) 4.5
Fair Value for Derivative Contingently Issuable Warrant Liabilities	National’s ($ in thousands) Warrants Beginning balance at December 31, 2016 $ 14,359 Change in fair value of derivative liability (6,169) Ending balance at March 31, 2017 $ 8,190
Avenue [Member] | Convertible Debt [Member]
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Avenue Convertible Note, at fair ($ in thousands) value Beginning balance at January 1, 2017 $ 200 Conversion into common shares (299) Change in fair value of convertible notes 99 Ending balance at June 30, 2017 $ -
Avenue [Member] | Warrant [Member]
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Avenue’s Warrant ($ in thousands) Liability Beginning balance at January 1, 2017 $ 12 Conversion into common shares (15) Change in fair value 3 Ending balance at June 30, 2017 $ -
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	June 30, 2017 Risk-free interest rate 1.140% - 1.298 % Expected dividend yield - % Expected term in years 0.50 - 1.41 Expected volatility 59.1 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Helocyte Convertible Note, at fair ($ in thousands) value Beginning balance at January 1, 2017 $ 4,487 Change in fair value of convertible notes 186 Ending balance at June 30, 2017 $ 4,673
Helocyte [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	June 30, 2017 Risk-free interest rate 1.720% -1.792 % Expected dividend yield - % Expected term in years 4.00 - 4.42 Expected volatility 70.0 % Strike price $ 0.44
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Fair Value of Derivative Warrant ($ in thousands) Liability Beginning balance at January 1, 2017 $ 167 Change in fair value of derivative liabilities (76) Ending balance at June 30, 2017 $ 91
National Holdings Corporation [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table shows the fair values hierarchy of National's financial instruments measured at fair value on a recurring basis on the Condensed Consolidated Balance Sheets as of March 31, 2017: Fair Value Measurement as of March 31, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 272 $ - $ - $ 272 Municipal bonds 2,928 - - 2,928 Restricted stock - 206 - 206 Total $ 3,200 $ 206 $ - $ 3,406 Liabilities National Securities sold, but not yet purchased at fair value Contingent consideration $ - $ - $ 630 $ 630 Corporate stocks 77 - - 77 Warrants - National - 8,190 8,190 Total $ 77 $ - $ 8,820 $ 8,897

Licenses Acquired (Tables)

Licenses Acquired (Tables)	6 Months Ended
	Jun. 30, 2017
Research and Development [Abstract]
Research and Development Arrangement, Contract to Perform for Others	1.8 3.1 For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2017 2016 2017 2016 Fortress $ 300 $ - $ 300 $ - Fortress Companies: Checkpoint - 2,060 400 2,060 Helocyte - - - 83 Mustang 1,500 - 2,075 - Caelum - - 219 - Cyprium - - 100 - Total $ 1,800 $ 2,060 $ 3,094 $ 2,143

Debt and Interest (Tables)

Debt and Interest (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	June 30, December 31, ($ in thousands) 2017 2016 Interest rate Maturity IDB Note $ 14,929 $ 14,929 2.25 % Feb - 2018 NSC Note 3,608 3,608 8.00 % Sep - 2018 2017 Subordinated Note Financing 3,254 - 8.00 % March - 2020 2017 Subordinated Note Financing 13,893 - 8.00 % May - 2020 2017 Subordinated Note Financing 1,820 - 8.00 % June - 2020 Opus Credit Facility 9,500 7,000 12.00 % Sep - 2018 Helocyte Convertible Note, at fair value 1,076 1,031 5.00% - 8.00% December 2017 Helocyte Convertible Note, at fair value 2,135 2,051 5.00% - 8.00% March - 2018 Helocyte Convertible Note, at fair value 1,032 991 5.00% - 8.00% April - 2018 Helocyte Convertible Note, at fair value 430 414 5.00% - 8.00% May - 2018 Avenue Convertible Note, at fair value - 200 5.00% - 8.00% June - 2018 Total notes payable 51,677 30,224 Less: Discount on notes payable 4,723 2,009 Total notes payable $ 46,954 $ 28,215
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: For the Three Months Ended June 30, For the Three Months Ended June 30, ($ in thousands) 2017 2016 2017 2016 IDB Note Interest $ 87 $ 79 $ 169 $ 159 Amortization of fees - - - 1 Total IDB Note 87 79 169 160 NSC Debt Interest 84 144 155 311 Amortization of fees 40 54 73 422 Total NSC Debt 124 198 228 733 NHLD Debt Interest 406 - 406 - Amortization of fees 175 - 175 - Total NHLD Debt 581 - 581 - Opus Credit Facility Interest 276 - 508 - Amortization of fees 241 - 454 - Total Opus Note 517 - 962 - LOC Fees Interest 7 3 15 7 Total LOC 7 3 15 7 Helocyte Convertible Note Interest 57 - 111 - Financing fee - 249 1 249 Total Helocyte Convertible Note 57 249 112 249 Avenue Convertible Note Interest 5 - 5 - Financing fee - - 3 - Total Helocyte Convertible Note 5 - 8 - D&O Insurance Interest 2 - 3 - Total D&O Insurance 2 - 3 - Total Interest Expense and Financing Fee $ 1,380 $ 529 $ 2,078 $ 1,149

Accrued Expenses and Other Lo34

Accrued Expenses and Other Long-Term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Components of Accrued Expenses and Other Long-Term Liabilities	Accrued expenses and other long-term liabilities, excluding National, consisted of the following: June 30, December 31, ($ in thousands) 2017 2016 Accrued expenses: Professional fees $ 1,748 $ 1,253 Salaries, bonuses and related benefits 2,295 2,846 Accrued Severance - 53 Ovamed manufacturing rights - short term component - 900 Research and development 2,914 394 Dr. Falk Pharma milestone 2,852 2,634 Other 2,564 2,002 Total accrued expenses $ 12,373 $ 10,082 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 5,026 5,014 Total other long-term liabilities $ 5,026 $ 5,014
National Holdings Corporation [Member]
Components of Accrued Expenses and Other Long-Term Liabilities	National's accounts payable and other accrued expenses as of March 31, 2017, consisted of the following: March 31, 2017 Legal $ 766 Audit 287 Telecommunications 187 Data Services 348 Regulatory 1,061 Settlements 1,131 Deferred rent 630 Contingent consideration payable 121 Other 2,592 Total $ 7,123

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	6 Months Ended
	Jun. 30, 2017
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities, as recorded on the Condensed Consolidated Balance Sheets are as follows: As of June 30, 2017 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation Caelum National Holdings Total NCI equity share $ 3,089 $ (236) $ 47,009 $ 22,026 $ (570) $ (1,677) $ (151) $ (3) $ 17,022 $ 86,509 Net loss attributed to non-controlling interests (314) (7) (5,027) (6,707) (48) (599) (83) (251) 4,872 (8,164) Non-controlling interests in consolidated entities $ 2,775 $ (243) $ 41,982 $ 15,319 $ (618) $ (2,276) $ (234) $ (254) $ 21,894 $ 78,345 As of December 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation National Holdings Total NCI equity share $ (494) $ (217) $ 12,376 $ 32,160 $ (192) $ (612) $ 4 $ 17,643 $ 60,668 Net loss attributed to non-controlling interests (349) (19) (1,805) (11,733) (355) (1,155) (158) (621) (16,195) Non-controlling interests in consolidated entities $ (843) $ (236) $ 10,571 $ 20,427 $ (547) $ (1,767) $ (154) $ 17,022 $ 44,473
Components Of Non-Controlling Interests In Loss Of Consolidated Entities	For the three months ended June 30, 2017 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Cellvation Caelum National Holdings Total Non-controlling interests in loss of consolidated entities $ (246) $ (3) $ (3,353) $ (3,972) $ 20 $ (276) $ (30) $ (106) $ 2,382 $ 5,584 Non-controlling ownership (3) 10.2 % 13.0 % 52.0 % 62.4 % 7.0 % 20.0 % 22.0 % 25.5 % 43.4 For the three months ended June 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (76) $ (5) $ (89) $ (3,476) $ (108) $ (157) $ (3,911) Non-controlling ownership (3) 11.5 % 13.0 % 10.0 % 64.3 % 8.1 % 20.4 % For the six months ended June 30, 2017 ($ in thousands) Avenue Coronado SO Mustang Checkpoint (1) JMC Helocyte Cellvation Caelum National Holdings Total Non-controlling interests in loss of consolidated entities $ (314) $ (7) $ (5,027) $ (6,707) $ (48) $ (599) $ (83) $ (251) $ 4,872 $ (8,164) Non-controlling ownership (3) 10.2 % 13.0 % 60.8 % 61.6 % 7.3 % 20.0 % 22.0 % 25.5 % 43.4 % For the six months ended June 30, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (184) $ (10) $ (159) $ (7,513) $ (229) $ (254) $ (8,349) Non-controlling ownership (3) 11.5 % 13.0 % 10.0 % 64.3 %(1) 8.1 % 20.4 % (1) - Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights. (2) - Mustang and Avenue are consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Mustang’s Class A preferred shares which provide super-majority voting rights (3) - Represents a weighted average of ownership during the periods presented.

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive at the end of the six months ended June 30, 2017 and 2016: For the Six Months Ended June 30, 2017 2016 Warrants to purchase Common Stock 603,316 515,068 Opus warrants to purchase Common Stock 1,880,000 - Options to purchase Common Stock 1,101,193 1,754,365 Unvested Restricted Stock 9,864,417 8,705,137 Unvested Restricted Stock Units 1,258,372 1,374,083 Total 14,707,298 12,348,653

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Schedule of Share-based Compensation, Activity	The following table summarizes the stock-based compensation expense from stock option awards, restricted common stock awards, employee stock purchase programs and warrants granted by Fortress for the three and six months ended June 30, 2017 and 2016: For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2017 2016 2017 2016 Employee awards $ 1,690 $ 1,969 $ 3,520 $ 3,553 Non-employee awards 23 3 36 6 Fortress Companies (1) 3,094 1,051 4,180 2,330 Total stock-based compensation expense $ 4,807 $ 3,023 $ 7,736 $ 5,889 (1) Consists of approximately $ 19,000 2.4 73,000 34,000 6,000 183,000 24,000 3.4 119,000 81,000 14,000 183,000 Consists of approximately $ 9,000 0.8 147,000 93,000 18,000 1.9 328,000 93,000
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable	The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies: Weighted average Weighted Total weighted remaining average average intrinsic contractual life Number of shares exercise price value (years) Options vested and expected to vest at December 31, 2016 1,130,501 $ 3.73 $ 602,451 4.93 Exercised (20,000) 1.37 67,600 - Options vested and expected to vest at June 30, 2017 1,110,501 $ 3.78 $ 1,826,461 4.46 Options vested and exercisable 1,085,501 $ 3.75 $ 1,826,461 4.43
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress’s restricted stock and restricted stock unit award activity, excluding activity related to Fortress Companies (which is discussed below): Weighted average Number of shares grant price Unvested balance at December 31, 2016 10,094,095 $ 2.49 Restricted stock granted 1,325,396 2.70 Restricted stock vested (213,333) 2.75 Restricted stock units granted 197,500 3.74 Restricted stock units forfeited (15,000) 2.98 Restricted stock units vested (138,750) 3.47 Unvested balance at June 30, 2017 11,249,908 $ 2.52
Schedule of Warrant Activities	The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies: Weighted average Total weighted remaining Weighted average average intrinsic contractual life Number of shares exercise price value (years) Outstanding as of December 31, 2016 2,263,453 $ 3.62 $ 79,800 4.74 Granted 608,505 3.61 518,724 4.86 Forfeited (123,007) 8.39 - - Outstanding as of June 30, 2017 2,748,951 $ 3.40 $ 940,203 3.77 Exercisable as of June 30, 2017 768,951 $ 4.37 $ 765,203 3.75
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of options granted in 2017 was estimated using the following assumptions: June 30, 2017 Risk-free interest rate 1.14% - 2.25 % Expected dividend yield - % Expected term in years 5.00 - 6.98 Expected volatility 95.25% - 105.95 %
Mustang Bio, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable	The following table summarizes stock option activities for the six months ended June 30, 2017: Stock Options Weighted Average Weighted Average Remaining Contractual Nonvested at December 31, 2016 - $ - - Options granted 1,241,675 $ 5.73 9.81 Options outstanding 1,241,675 5.73 9.81 Options vested and exercisable at June 30, 2017 - $ - -
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The value associated with the market award vesting was determined utilizing a Monte Carlo simulation valuation methodology and the following assumptions: June 30, Risk-free interest rate 2.38 % Expected dividend yield - % Expected term in years 5.5 to 10.0 Expected volatility 77.3 %

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Schedule of Effective Date and Equity Fee Payble	The following table summarizes, by subsidiary, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the subsidiaries’ certificates of incorporation. PIK Dividend as a % of fully diluted outstanding Class of Stock Fortress Company Effective Date (1) capitalization Issued Helocyte March 20, 2015 2.5 % Common Stock Avenue February 17, 2015 2.5 % Common Stock Mustang March 13, 2015 2.5 % Common Stock Checkpoint March 17, 2015 0.0 % (2) Common Stock Cellvation October 31, 2016 2.5 % Common Stock Caelum January 1, 2017 2.5 % Common Stock Cyprium March 13, 2017 2.5 % Common Stock (1) - Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement. (2) - Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5
Schedule of The Effective Date and Annual Management Services agreement Fee Income Expense	The following table summarizes, by subsidiary, the effective date of the MSA and the annual consulting fee payable by the subsidiary to the Company in quarterly installments: ($ in thousands) Fortress Annual MSA Fee Company Effective Date R&D G&A (Income)/Expense Helocyte March 20, 2015 $ 250 $ 250 $ 500 Avenue February 17, 2015 250 250 500 Mustang March 13, 2015 250 250 500 Checkpoint March 17, 2015 250 250 500 Cellvation October 31, 2016 250 250 500 Caelum January 1, 2017 250 250 500 Cyprium March 13, 2017 250 250 500 Fortress (1,750) (1,750) (3,500) Consolidated (Income)/Expense $ - $ - $ -

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold Pharmaceutical and Dermatology Biotechnology ($ in thousands) Products Product Three Months Ended June 30, 2017 Sales Development National Consolidated Net Revenue $ 4,054 $ 350 $ 46,293 $ 50,697 Direct cost of goods (878) - - (878) Sales and marketing costs (2,610) - - (2,610) Research and development - (13,483) - (13,483) General and administrative (293) (8,231) - (8,524) National Expenses - - (48,395) (48,395) Segment loss from operations $ 273 $ (21,364) $ (2,102) $ (23,193) Segment assets $ 5,447 $ 167,787 $ 76,612 $ 249,846 Dermatology Pharmaceutical and Products Biotechnology Product Three Months Ended June 30, 2016 Sales Development Consolidated Net Revenue $ 982 $ 1,248 $ 2,230 Direct cost of goods (324) - (324) Sales and marketing costs (1,998) - (1,998) Research and development - (8,407) (8,407) General and administrative - (6,637) (6,637) Segment loss from operations $ (1,340) $ (13,796) $ (15,136) Segment assets $ 3,058 $ 95,004 $ 98,062 Pharmaceutical and Dermatology Biotechnology ($ in thousands) Products Product Six Months Ended June 30, 2017 Sales Development National Consolidated Net Revenue $ 6,139 $ 1,043 $ 88,197 $ 95,379 Direct cost of goods (1,347) - - (1,347) Sales and marketing costs (4,877) - - (4,877) Research and development - (21,887) - (21,887) General and administrative (612) (15,897) - (16,509) National Expenses - - (91,529) (91,529) Segment loss from operations $ (697) $ (36,741) $ (3,332) $ (40,770) Segment assets $ 5,447 $ 167,787 $ 76,612 $ 249,846 Dermatology Pharmaceutical and Products Biotechnology Six Months Ended June 30, 2016 Sales Product Development Consolidated Net Revenue $ 1,364 $ 1,526 $ 2,890 Direct cost of goods (324) - (324) Sales and marketing costs (3,884) - (3,884) Research and development - (16,243) (16,243) General and administrative - (12,666) (12,666) Segment loss from operations $ (2,844) $ (27,383) $ (30,227) Segment assets $ 3,058 $ 95,004 $ 98,062

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended	6 Months Ended
	Apr. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Accounting Policies [Line Items]
Short-term Investments		$ 20,038,000		$ 0
Payments to Acquire Short-term Investments	$ 20,000,000	20,038,000	$ 0
Short Term Investment Maximum Amount Per Institution		$ 250,000

National Holdings Corporation41

National Holdings Corporation Acquisition – Intangible Assets - Amortization is calculated using the straight-line method over the estimated useful lives (Detail)	6 Months Ended
	Jun. 30, 2017
Trademarks [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Customer Lists [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years

National Holdings Corporation42

National Holdings Corporation Acquisition – Intangible Assets - gross carrying amounts related to acquired intangible assets (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Intangible assets at December 31, 2016	$ 15,991
Amortization expense	(819)	$ 0
Intangible assets at March 31, 2017	$ 15,172

National Holdings Corporation43

National Holdings Corporation Acquisition – Intangible Assets - future amortization of these intangible assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Total	$ 16,533	$ 17,408
National Holdings Corporation [Member]
Six Months Ended December 31, 2017	831
Year Ended December 31, 2018	1,649
Year Ended December 31, 2019	1,649
Year Ended December 31, 2020	1,654
Year Ended December 31, 2021	1,649
Thereafter	7,740
Total	$ 15,172

National Holdings Corporation44

National Holdings Corporation Acquisition – Intangible Assets - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2017	Mar. 17, 2017	Dec. 31, 2016	Sep. 09, 2016
Common Stock Par Or Stated Value Per Share	$ 0.001		$ 0.001
Goodwill	$ 18,645		$ 18,645
National Holdings Corporation [Member]
Business Acquisition, Percentage of Voting Interests Acquired	56.60%	56.60%		56.60%
Business Acquisition, Share Price				$ 3.25
Common Stock Par Or Stated Value Per Share				$ 0.02

Broker-Dealers and Clearing O45

Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations	$ 2,813		$ 3,357
Broker -Dealers And clearing Organisation [Member]
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations		$ 2,800
Allowance for Doubtful Accounts Receivable		500
Broker -Dealers And clearing Organisation [Member] | Other Receivable [Member]
Brokers And Dealers [Line Items]
Accounts Receivable, Net		$ 6,100

Forgivable Loans Receivable - A

Forgivable Loans Receivable - Additional Information (Detail)	Jun. 30, 2017
Forgivable Loan Receivable [Member]
Debt Instrument, Interest Rate, Stated Percentage	9.00%

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 7,329	$ 7,376
Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	6,799	6,657
Less: accumulated depreciation	(801)	(445)
Property and equipment, net	5,998	6,212
Computer Equipment [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 517	440
Useful Life (Years)	3 years
Furniture and Fixtures [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 931	821
Useful Life (Years)	5 years
Leasehold Improvements [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 5,351	$ 5,396
Property, Plant and Equipment, Estimated Useful Lives	Various

Property and Equipment - Schedu

Property and Equipment - Schedule Of Interest Expenses For Debt Arrangements (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, net		$ 7,329	$ 7,376
National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 1,554
Less: accumulated depreciation	(223)
Property and equipment, net	1,331
Equipment [Member] | National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 861
Property, Plant and Equipment, Estimated Useful Lives	5 years
Furniture And Fixtures [Member] | National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 82
Property, Plant and Equipment, Estimated Useful Lives	5 years
Leaseholds And Leasehold Improvements [Member] | National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 335
Property, Plant and Equipment, Estimated Useful Lives	Lesser of useful life or term of lease
Capital leases (primarily composed of computer equipment) [Member] | National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 276
Property, Plant and Equipment, Estimated Useful Lives	5 years

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 180	$ 82	$ 543	$ 74

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Liabilities And Convertible Notes At Fair Value (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		1.93%
Expected dividend yield		0.00%
Expected term in years		4 years 6 months
Expected volatility		97.76%
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield	0.00%
Expected volatility	59.10%
Helocyte [Member] | Minimum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.14%
Expected term in years	6 months
Helocyte [Member] | Maximum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.298%
Expected term in years	1 year 4 months 28 days
Helocyte [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield	0.00%
Expected volatility	70.00%
Strike price	$ 0.44
Helocyte [Member] | Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.72%
Expected term in years	4 years
Helocyte [Member] | Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.792%
Expected term in years	4 years 5 months 1 day

Fair Value Measurements - Deriv

Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2017	Jun. 30, 2017
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Conversion into common shares		$ (1,064)
National [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	$ 14,359	14,359
Change in fair value	(6,169)
Fair value at end of period:	8,190
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	200	200
Conversion into common shares		(299)
Change in fair value		99
Fair value at end of period:		0
Avenue [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	302	302
Conversion into common shares		(750)
Change in fair value		448
Fair value at end of period:		0
Avenue [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	12	12
Conversion into common shares		(15)
Change in fair value		3
Fair value at end of period:		0
Helocyte [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	167	167
Change in fair value		(76)
Fair value at end of period:		91
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	$ 4,487	4,487
Change in fair value		186
Fair value at end of period:		$ 4,673

Fair Value Measurements - Natio

Fair Value Measurements - National Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016
Assets
Long-term investments, at fair value	$ 903		$ 1,414
Total	903		1,414
Liabilities
Liabilities	4,764		5,168
National Holdings Corporation [Member]
Assets
Total		$ 3,406
Liabilities
Liabilities		8,897
Contingently Issuable Warrant [Member]
Liabilities
Liabilities			302
Warrant [Member]
Liabilities
Liabilities	91		179
Helocyte Convertible Note One [Member]
Liabilities
Liabilities	4,673		4,487
Avenue Convertible Note [Member]
Liabilities
Liabilities			200
Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		272
Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		2,928
Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		206
Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		77
Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		8,190
Contingent Consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		630
Fair Value, Inputs, Level 1 [Member]
Assets
Long-term investments, at fair value	0		0
Total	0		0
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | National Holdings Corporation [Member]
Assets
Total		3,200
Liabilities
Liabilities		77
Fair Value, Inputs, Level 1 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities			0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities			0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		272
Fair Value, Inputs, Level 1 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		2,928
Fair Value, Inputs, Level 1 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		77
Fair Value, Inputs, Level 1 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member]
Assets
Long-term investments, at fair value	0		0
Total	0		0
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | National Holdings Corporation [Member]
Assets
Total		206
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities			0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities			0
Fair Value, Inputs, Level 2 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 2 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 2 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		206
Fair Value, Inputs, Level 2 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member]
Assets
Long-term investments, at fair value	903		1,414
Total	903		1,414
Liabilities
Liabilities	4,764		5,168
Fair Value, Inputs, Level 3 [Member] | National Holdings Corporation [Member]
Assets
Total		0
Liabilities
Liabilities		8,820
Fair Value, Inputs, Level 3 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities			302
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Liabilities
Liabilities	91		179
Fair Value, Inputs, Level 3 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	$ 4,673		4,487
Fair Value, Inputs, Level 3 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities			$ 200
Fair Value, Inputs, Level 3 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		8,190
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		$ 630

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Financial Instruments (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 20,941
Conversion into common shares	(1,064)
Issuance of warrants	0
Change in fair value of investments	(511)
Change in fair value of convertible notes	285
Change in fair value of derivative liabilities	(5,794)
Balance	13,857
Helocyte Convertible Note At Fair Value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	4,487
Conversion into common shares	0
Issuance of warrants	0
Change in fair value of investments	0
Change in fair value of convertible notes	186
Change in fair value of derivative liabilities	0
Balance	4,673
Avenue Convertible Note, at fair value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	200
Conversion into common shares	(299)
Issuance of warrants	0
Change in fair value of investments	0
Change in fair value of convertible notes	99
Change in fair value of derivative liabilities	0
Balance	0
Warrants Issued Issuable [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	14,661
Conversion into common shares	(750)
Issuance of warrants	(8,190)
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	(5,721)
Balance	0
Warrant liabilities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	179
Conversion into common shares	(15)
Issuance of warrants	8,190
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	(73)
Balance	8,281
Investment In Laser Device [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	250
Conversion into common shares	0
Issuance of warrants	0
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	0
Balance	250
Investment In Origo [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	1,164
Conversion into common shares	0
Issuance of warrants	0
Change in fair value of investments	(511)
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	0
Balance	$ 653

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	1 Months Ended	6 Months Ended
	Mar. 17, 2014	Jun. 30, 2017	Dec. 31, 2016	Dec. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments	$ 250,000	$ 300,000	$ 300,000
Equity Method Investment, Ownership Percentage	35.00%
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total		500,000
Investment Owned, at Fair Value		$ 3,406,000	$ 2,357,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.02
Equity Securities Called by Warrant				$ 10,000
Common Stock Par Or Stated Value Per Share		$ 0.001	$ 0.001
Exercise Price Of Warrant Discount Percentage		33.00%
Debt Conversion, Converted Instrument, Shares Issued		47,949
Origo Acquisition Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value		$ 700,000
Fair Value Assumptions Probability Of Business Combination		24.30%
Working Capital Note Convertible To Equity		$ 300,000
National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants		43.40%
Percentage of outstanding shares, Tendered		80.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.25
Warrants Not Settleable in Cash, Fair Value Disclosure		$ 5,400,000
Debt Instrument, Face Amount		$ 3,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		125,000
Avenue Therapeutics, Inc. [Member] | IPO [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Issued During Period, Value, New Issues		$ 37,900,000
Stock Issued During Period, Shares, New Issues		6,300,000
Common Stock Par Or Stated Value Per Share		$ 6
Westpark [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		4.02
Common Stock Par Or Stated Value Per Share		$ 6
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,488
Exercise Price Of Warrant Discount Percentage		33.00%
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price		$ 0.18
Fair Value Assumptions, Expected Volatility Rate		0.24%
Private Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price		$ 9.73
Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares Received Under Purchase Agreement	$ 13,409,962
Percentage Of Shares Received Under Purchase Agreement	83.00%
Preferred Units, Issued	16,091,954

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 1,800	$ 2,060	$ 3,094	$ 2,143
Fortress [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	300	0	300	0
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	2,060	400	2,060
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	0	0	83
Mustang Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	1,500	0	2,075	0
Caelum Biosciences, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	0	219	0
Cyprium Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 0	$ 0	$ 100	$ 0

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($)

Jul. 03, 2017

May 31, 2017

Apr. 25, 2017

Mar. 31, 2017

Feb. 17, 2017

Jan. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 1,800,000

$ 2,060,000

$ 3,094,000

$ 2,143,000

City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

$ 100,000

Revenue Recognition Milestone Method Payments Due

100,000

Effcon Laboratories, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

300,000

Payment of Upfront Fees

$ 200,000

Revenue Recognition Milestone Method Payments Due

$ 2,300,000

Royalty Guarantees, Commitments, Amount

$ 1,600,000

Jubilant Biosys Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 400,000

Royalty Revenue

$ 100,000

1,000,000

$ 600,000

1,000,000

National Institute of Child Health and Human Development [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Milestone Fees

$ 100,000

Columbia University [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Stock Issued During Period, Shares, Purchase of Assets

1,050,000

Shares Issued, Price Per Share

$ 0.028

$ 0.028

Stock Issued During Period, Value, Purchase of Assets

$ 29,000

Payment of Upfront Milestone Fees

$ 200,000

Revenue Recognition Milestone Method Payments Due

$ 5,500,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

10.00%

Collaborative Agreements with TGTX [Member] | NeuPharma [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

$ 9,000

3,000

38,000

20,000

Checkpoint Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 0

$ 2,060,000

400,000

$ 2,060,000

Payment of Upfront Fees

$ 2,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

[1],[2]

62.40%

64.30%

62.40%

64.30%

Checkpoint Therapeutics, Inc [Member] | Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Stock Issued During Period, Value, Purchase of Assets

$ 1,800,000

$ 3,100,000

UCLA License [Member] | University of California [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 200,000

A&R CD123 License [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

14,500,000

A&R IL-13 License [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 300,000

Revenue Recognition Milestone Method Payments Due

$ 14,500,000

CS1 Technology License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

$ 14,900,000

Annual Maintenance Fee Payable

50,000

CS1 Technology License [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 600,000

PSCA Technology License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

14,900,000

Annual Maintenance Fee Payable

50,000

PSCA Technology License [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

300,000

HER2 Technology License [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue Recognition Milestone Method Payments Due

14,900,000

Annual Maintenance Fee Payable

$ 50,000

HER2 Technology License [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 600,000

[1]

Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.

[2]

Represents a weighted average of ownership during the periods presented.

Sponsored Research Agreements -

Sponsored Research Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2017	Feb. 17, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Checkpoint Therapeutics, Inc [Member]
Reimbursement Of Cost Recognized As Revenue			$ 200,000	$ 200,000	$ 400,000	$ 500,000
Helocyte Inc [Member] | Pentamer Sponsored Research Agreement [Member]
Payments For Research And Development Expenses					12,000
Payment of Upfront Milestone Fees	$ 1,500,000
Helocyte Inc [Member] | Pep Vax [Member]
Payments For Research And Development Expenses					200,000	1,000,000
Helocyte Inc [Member] | Triplex [Member]
Payments For Research And Development Expenses			500,000	0	1,000,000	1,000,000
Mustang Bio, Inc [Member]
Research And Development Expense Payable Milestone Payment	$ 2,000,000		2,000,000		2,000,000
Payments For Research And Development Expenses			500,000	$ 500,000	1,000,000	$ 1,000,000
City Of Hope [Member] | AR IL-13 License [Member]
Research And Development Expense			11,000		1,000,000
Payment of Upfront Milestone Fees		$ 10,000
Revenue Recognition Milestone Method Payments Due Over Three Years		200,000
Revenue Recognition Milestone Method Payments Due		100,000
City Of Hope [Member] | AR CD123 License [Member]
Research And Development Expense			$ 22,000		$ 600,000
Payment of Upfront Milestone Fees		20,000
Revenue Recognition Milestone Method Payments Due Over Three Years		200,000
Revenue Recognition Milestone Method Payments Due		$ 100,000

Intangibles, net - Additional I

Intangibles, net - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets			$ 0	$ 350,000
Cost of Goods Sold, Amortization			267,000	21,000
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets			1,600,000
Cost of Goods Sold, Amortization	$ 100,000	$ 21,000	$ 300,000	$ 21,000

Debt and Interest - Long-term d

Debt and Interest - Long-term debt (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Debt [Line Items]
Total notes payable	$ 51,677	$ 30,224
Less: Discount of notes payable	4,723	2,009
Total notes payable, net	46,954	28,215
IDB Note [Member]
Debt [Line Items]
Total notes payable	$ 14,929	14,929
Interest Rate	2.25%
Maturity Date	Feb - 2018
NSC Note [Member]
Debt [Line Items]
Total notes payable	$ 3,608	3,608
Interest Rate	8.00%
Maturity Date	Sep - 2018
2017 Subordinated Note Financing One [Member]
Debt [Line Items]
Total notes payable	$ 3,254	0
Interest Rate	8.00%
Maturity Date	March - 2020
Avenue Convertible Note [Member]
Debt [Line Items]
Total notes payable	$ 0	200
Maturity Date	June - 2018
Avenue Convertible Note [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Avenue Convertible Note [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Opus Credit Facility [Member]
Debt [Line Items]
Total notes payable	$ 9,500	7,000
Interest Rate	12.00%
Maturity Date	Sep - 2018
Helocyte Convertible Note One [Member]
Debt [Line Items]
Total notes payable	$ 1,076	1,031
Maturity Date	December 2,017
Helocyte Convertible Note One [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note One [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Two [Member]
Debt [Line Items]
Total notes payable	$ 2,135	2,051
Maturity Date	March - 2018
Helocyte Convertible Note Two [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note Two [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Three [Member]
Debt [Line Items]
Total notes payable	$ 1,032	991
Maturity Date	April - 2018
Helocyte Convertible Note Three [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note Three [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note four [Member]
Debt [Line Items]
Total notes payable	$ 430	414
Maturity Date	May - 2018
Helocyte Convertible Note four [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note four [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
2017 Subordinated Note Financing Two [Member]
Debt [Line Items]
Total notes payable	$ 13,893	0
Interest Rate	8.00%
Maturity Date	May - 2020
2017 Subordinated Note Financing Three [Member]
Debt [Line Items]
Total notes payable	$ 1,820	$ 0
Interest Rate	8.00%
Maturity Date	June - 2020

Debt and Interest - Schedule of

Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Debt [Line Items]
Total Interest Expense and Financing Fee	$ 1,380	$ 529	$ 2,078	$ 1,149
LOC Fees [Member]
Debt [Line Items]
Interest	7	3	15	7
Interest and Debt Expense	7	3	15	7
IDB Note [Member]
Debt [Line Items]
Interest	87	79	169	159
Amortization of fees	0	0	0	1
Interest and Debt Expense	87	79	169	160
NSC Debt [Member]
Debt [Line Items]
Interest	84	144	155	311
Amortization of fees	40	54	73	422
Interest and Debt Expense	124	198	228	733
NHLD Debt [Member]
Debt [Line Items]
Interest	406	0	406	0
Amortization of fees	175	0	175	0
Interest and Debt Expense	581	0	581	0
Opus Credit Facility [Member]
Debt [Line Items]
Interest	276	0	508	0
Amortization of fees	241	0	454	0
Interest and Debt Expense	517	0	962	0
Avenue Convertible Note [Member]
Debt [Line Items]
Interest	5	0	5	0
Financing fee	0	0	3	0
Interest and Debt Expense	5	0	8	0
Helocyte Convertible Note [Member]
Debt [Line Items]
Interest	57	0	111	0
Financing fee	0	249	1	249
Interest and Debt Expense	57	249	112	249
D&O Insurance [Member]
Debt [Line Items]
Interest	2	0	3	0
Interest and Debt Expense	$ 2	$ 0	$ 3	$ 0

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($)	May 01, 2017	Jun. 30, 2017	May 31, 2017	Mar. 17, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Feb. 13, 2014
Debt [Line Items]
Warrant exercise price		$ 4.02			$ 4.02
Debt discount recorded		$ 4,723,000			$ 4,723,000		$ 2,009,000
Notes Payable		$ 46,954,000			$ 46,954,000		$ 28,215,000
Maximum [Member]
Debt [Line Items]
Warrant exercise price		$ 4.75			$ 4.75
Israel Discount Bank Of New York [Member]
Debt [Line Items]
Debt Instrument, Face Amount								$ 15,000,000
Notes Payable		$ 14,900,000			$ 14,900,000
Debt Instrument, Collateral Amount		15,000,000			15,000,000
Opus Credit Facility [Member]
Debt [Line Items]
Class Of Warrant Or Right Discount On Warrant		1,600,000			1,600,000
Warrants and Rights Outstanding		$ 9,500,000			$ 9,500,000
NSC 2017 Note [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Debt Instrument, Face Amount						$ 3,250,000
Debt Instrument, Maturity Date, Description					Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion.
Paid-in-Kind Interest,Percentage						7.00%
Line of Credit Facility, Current Borrowing Capacity						$ 50,000,000
Percentage Of Placement Agent Fee				10.00%	10.00%
Warrants on Sale Price of Note,Percentage		10.00%		10.00%	10.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		508,505			508,505
NSC 2017 Note [Member] | First Closing [Member]
Debt [Line Items]
Debt discount recorded		$ 200,000			$ 200,000
Proceeds from Fees Received					$ 325,400
NSC 2017 Note [Member] | Secoud Closing [Member]
Debt [Line Items]
Warrant exercise price	$ 3.65
Proceeds from Notes Payable	$ 8,600,000
Proceeds from Fees Received	$ 900,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	234,438	87,946			87,946
NSC 2017 Note [Member] | Third Closing [Member]
Debt [Line Items]
Warrant exercise price			$ 3.61
Proceeds from Notes Payable			$ 5,300,000
Proceeds from Fees Received			$ 500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			147,806
NSC 2017 Note [Member] | Fourth Closing [Member]
Debt [Line Items]
Warrant exercise price		$ 4.75			$ 4.75
Proceeds from Notes Payable		$ 1,800,000
Proceeds from Fees Received		$ 200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		38,315			38,315
NSC 2017 Note [Member] | Maximum [Member]
Debt [Line Items]
Debt Instrument, Face Amount						$ 40,000,000

Accrued Expenses and Other Lo62

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accrued expenses:
Professional fees	$ 1,748	$ 1,253
Salaries, bonuses and related benefits	2,295	2,846
Accrued Severance	0	53
Ovamed manufacturing rights - short term component	0	900
Research and development	2,914	394
Dr. Falk Pharma milestone	2,852	2,634
Other	2,564	2,002
Total accrued expenses	12,373	10,082
Other long-term liabilities:
Deferred rent and long-term lease abandonment charge	5,026	5,014
Total other long-term liabilities	$ 5,026	$ 5,014

Accrued Expenses and Other Lo63

Accrued Expenses and Other Long-Term Liabilities- Accounts Payable and Other Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016
Legal	$ 1,748		$ 1,253
Other	2,564		2,002
Total	$ 24,995		$ 23,871
National Holdings Corporation [Member]
Legal		$ 766
Audit		287
Telecommunications		187
Data Services		348
Regulatory		1,061
Settlements		1,131
Deferred rent		630
Contingent consideration payable		121
Other		2,592
Total		$ 7,123

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended			12 Months Ended
	Jun. 30, 2017		Jun. 30, 2016	Jun. 30, 2017		Jun. 30, 2016	Dec. 31, 2016
Noncontrolling Interest [Line Items]
NCI equity share				$ 86,509			$ 60,668
Net loss attributed to non-controlling interests	$ (5,584)		$ (3,911)	(8,164)		$ (8,349)	(16,195)
Non-controlling interests in consolidated entities	78,345			78,345			44,473
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share				3,089			(494)
Net loss attributed to non-controlling interests	(246)		(76)	(314)		(184)	(349)
Non-controlling interests in consolidated entities	2,775			2,775			(843)
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(236)			(217)
Net loss attributed to non-controlling interests	(3)		(5)	(7)		(10)	(19)
Non-controlling interests in consolidated entities	(243)			(243)			(236)
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share				47,009			12,376
Net loss attributed to non-controlling interests	(3,353)		(89)	(5,027)		(159)	(1,805)
Non-controlling interests in consolidated entities	41,982			41,982			10,571
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share				22,026			32,160
Net loss attributed to non-controlling interests	(3,972)	[1]	(3,476)	(6,707)	[1]	(7,513)	(11,733)
Non-controlling interests in consolidated entities	15,319			15,319			20,427
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(570)			(192)
Net loss attributed to non-controlling interests	20		(108)	(48)		(229)	(355)
Non-controlling interests in consolidated entities	(618)			(618)			(547)
Helocyte [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(1,677)			(612)
Net loss attributed to non-controlling interests	(276)		$ (157)	(599)		$ (254)	(1,155)
Non-controlling interests in consolidated entities	(2,276)			(2,276)			(1,767)
Cellvation [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(151)			4
Net loss attributed to non-controlling interests	(30)			(83)			(158)
Non-controlling interests in consolidated entities	(234)			(234)			(154)
Caelum [Member]
Noncontrolling Interest [Line Items]
NCI equity share				(3)
Net loss attributed to non-controlling interests	(106)			(251)
Non-controlling interests in consolidated entities	(254)			(254)
National Holdings [Member]
Noncontrolling Interest [Line Items]
NCI equity share				17,022			17,643
Net loss attributed to non-controlling interests	2,382			4,872			(621)
Non-controlling interests in consolidated entities	$ 21,894			$ 21,894			$ 17,022
[1]	Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.

Non-Controlling Interests - S65

Non-Controlling Interests - Summary Of Components of Non-Controlling Interests in Loss of Consolidated Entities (Detail) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended			12 Months Ended
		Jun. 30, 2017		Jun. 30, 2016	Jun. 30, 2017		Jun. 30, 2016	Dec. 31, 2016
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ (5,584)		$ (3,911)	$ (8,164)		$ (8,349)	$ (16,195)
Avenue [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ (246)		$ (76)	$ (314)		$ (184)	(349)
Non-controlling ownership	[1]	10.20%		11.50%	10.20%		11.50%
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ (3)		$ (5)	$ (7)		$ (10)	(19)
Non-controlling ownership	[1]	13.00%		13.00%	13.00%		13.00%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ (3,353)		$ (89)	$ (5,027)		$ (159)	(1,805)
Non-controlling ownership	[1]	52.00%		10.00%	52.00%		10.00%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ (3,972)	[2]	$ (3,476)	$ (6,707)	[2]	$ (7,513)	(11,733)
Non-controlling ownership	[1],[2]	62.40%		64.30%	62.40%		64.30%
JMC [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ 20		$ (108)	$ (48)		$ (229)	(355)
Non-controlling ownership	[1]	7.00%		8.10%	7.00%		8.10%
Helocyte [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ (276)		$ (157)	$ (599)		$ (254)	(1,155)
Non-controlling ownership	[1]	20.00%		20.40%	20.00%		20.40%
Cellvation [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ (30)			$ (83)			(158)
Non-controlling ownership	[1]	22.00%			22.00%
National Holdings [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ 2,382			$ 4,872			$ (621)
Non-controlling ownership	[1]	43.40%			43.40%
Caelum [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities		$ (106)			$ (251)
Non-controlling ownership	[1]	25.50%			25.50%
[1]	Represents a weighted average of ownership during the periods presented.
[2]	Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.

Net Loss per Common Share - Com

Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	14,707,298	12,348,653
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	603,316	515,068
Opus warrants to purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,880,000	0
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,101,193	1,754,365
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	9,864,417	8,705,137
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,258,372	1,374,083

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 4,807	$ 3,023	$ 7,736	$ 5,889
Fortress Companies [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	[1]	3,094	1,051	4,180	2,330
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		1,690	1,969	3,520	3,553
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 23	$ 3	$ 36	$ 6
[1]	Consists of approximately $19,000 of Avenue's compensation expenses, approximately $2.4 million of Checkpoint's compensation expense, approximately $73,000 of JMC's compensation expenses, approximately $34,000 of Helocyte's compensation expenses, approximately $6,000 of Cellvation's compensation expenses and approximately $183,000 of of NHLD's compensation expenses on stock and option grants for the three months ended June 30, 2017 and consists of approximately $24,000 of Avenue's compensation expenses, approximately $3.4 million of Checkpoint's compensation expense, approximately $119,000 of JMC's compensation expenses, approximately $81,000 of Helocyte's compensation expenses, approximately $14,000 of Cellvation's compensation expenses and approximately $183,000 of of NHLD's compensation expenses on stock and option grants for the six months ended June 30, 2017. Consists of approximately $9,000 of Avenue's compensation expenses, approximately $0.8 million of Checkpoint's compensation expense, approximately $147,000 of JMC's compensation expenses and approximately $93,000 of Helocyte's compensation expenses on stock grants for the three months ended June 30, 2016, and approximately $18,000 of Avenue's compensation expenses, approximately $1.9 million of Checkpoint's compensation expense, approximately $328,000 of JMC's compensation expenses and approximately $93,000 of Helocyte's compensation expenses on stock grants for the six months ended June 30, 2016.

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Options exercised	(20,000)
Number of shares, Options vested and exercisable	1,085,501
Weighted Average Exercise Price, Options exercised	$ 1.37
Total Weighted Average Intrinsic Value, Options vested and exercisable	$ 1,826,461
Total weighted average intrinsic value , Options Exercisable	$ 1,826,461,000
Number of shares, Options vested and expected to vest	1,130,501
Number of shares, Options vested and expected to vest	1,110,501	1,130,501
Weighted average exercise price, Options vested and expected to vest	$ 3.73
Weighted average exercise price, Options vested and expected to vest	3.78	$ 3.73
Weighted average exercise price, Options vested and exercisable	$ 3.75
Total Weighted average intrinsic value, Options vested and expected to vest	$ 602,451,000
Total Weighted average intrinsic value, Options vested and expected to vest	$ 1,826,461,000	$ 602,451,000
Weighted average remaining contractual life (years), Options vested and expected to vest	4 years 5 months 16 days	4 years 11 months 5 days
Weighted average remaining contractual life (years), Options vested and exercisable	4 years 5 months 5 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 67,600,000

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Unvested balance | shares	10,094,095
Number of shares, Restricted stock granted | shares	1,325,396
Number of shares, Restricted stock vested | shares	(213,333)
Number of shares, Restricted stock units granted | shares	197,500
Number of shares, Restricted stock units forfeited | shares	(15,000)
Number of shares, Restricted stock units vested | shares	(138,750)
Number of shares, Unvested balance | shares	11,249,908
Weighted average grant price, Unvested balance | $ / shares	$ 2.49
Weighted average grant price, Restricted stock granted | $ / shares	2.7
Weighted average grant price, Restricted stock vested | $ / shares	2.75
Weighted average grant price, Restricted stock units granted | $ / shares	3.74
Weighted average grant price, Restricted stock units forfeited | $ / shares	2.98
Weighted average grant price, Restricted stock units vested | $ / shares	3.47
Weighted average grant price, Unvested balance | $ / shares	$ 2.52

Stockholders' Equity - Summariz

Stockholders' Equity - Summarizes Fortress warrant activities (Detail) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Subsidiary or Equity Method Investee [Line Items]
Number of shares, Outstanding	2,263,453
Number of shares, Granted	608,505
Forfeited	(123,007)
Number of shares, Outstanding	2,748,951	2,263,453
Number of shares, Exercisable	768,951
Weighted average exercise price, Outstanding	$ 3.62
Weighted average exercise price, Granted	3.61
Weighted average exercise price, Forfeited	8.39
Weighted average exercise price, Outstanding	$ 3.4	$ 3.62
Total weighted average instrinsic value, Outstanding	$ 940,203	$ 79,800
Weighted average exercise price, Exercisable	$ 4.37
Total weighted average instrinsic value, Outstanding	$ 79,800
Total weighted average intrinsic value, Granted	518,724
Total weighted average instrinsic value, Forfeited	0
Total weighted average intrinsic value, Exercisable	$ 765,203
Weighted average remaining contractual life, Granted (years)	4 years 10 months 10 days
Weighted average remaining contractual life, Exercisable (years)	3 years 9 months
Weighted average remaining contractual life, Forfeited (years)	0 years
Weighted average remaining contractual life (years), Outstanding	3 years 9 months 7 days	4 years 8 months 26 days

Stockholders' Equity - Fair val

Stockholders' Equity - Fair value of options (Detail)	6 Months Ended
	Jun. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, Minimum	1.14%
Risk-free interest rate, Maximum	2.25%
Expected dividend yield	0.00%
Expected volatility, Minimum	95.25%
Expected volatility, Maximum	105.95%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	5 years
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 11 months 23 days

Stockholders_ Equity - Monte Ca

Stockholders’ Equity - Monte Carlo simulation valuation methodology (Detail)	6 Months Ended
	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 11 months 23 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Mustang Bio, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.38%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	77.30%
Mustang Bio, Inc [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	10 years
Mustang Bio, Inc [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 6 months

Stockholders_ Equity - Mustang

Stockholders’ Equity - Mustang Bio stock option activities (Detail)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number	1,085,501
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Granted, Weighted Average Remaining Contractual Term	9 years 9 months 22 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Outstanding, Weighted Average Remaining Contractual Term	9 years 9 months 22 days
Mustang Bio, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,241,675
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	1,241,675
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number	0
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Granted, Weighted Average Price | $ / shares	$ 5.73
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Outstanding , Weighted Average Price | $ / shares	$ 5.73

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Apr. 07, 2017	Sep. 09, 2016	Mar. 31, 2017	Jan. 31, 2017	Jan. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period						85.00%		85.00%
Employee Stock Purchase Plan to eligible employees, compensation expense recognized						$ 40,000	$ 30,000	$ 75,000	$ 56,000
General and Administrative Expense						$ 8,524,000	6,637,000	16,509,000	12,666,000
Allocated Share-based Compensation Expense								$ 3,200,000	2,400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 4.02		$ 4.02
Share-based Compensation								$ 7,736,000	5,889,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%
Warrants Issued				853,677
Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage Of Placement Agent Fee			10.00%
Payments of Stock Issuance Costs			$ 42,000
Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value								$ 1,500,000		$ 1,400,000
Capital Units, Authorized				100,000,000
Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense								$ 4,300,000	3,500,000
Checkpoint [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 2,400,000
Dr. Rosenwald [Member] | Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				552,698	510,434
Mustang [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Proceeds from Issuance of Private Placement				$ 8,536,774
Mustang [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 8.50		$ 8.50
Stock Issued During Period, Value of Warrants Excercised								$ 65,000
Avenue Therapeutics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research And Development Expense						$ 10,000	4,000	12,000	9,000
General and Administrative Expense						10,000	4,000	12,000,000,000	9,000
Allocated Share-based Compensation Expense						19,000	9,000	24,000	18,000
Proceeds from issuance of Common stock								34,500,000
Mustang Bio, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options						2,100,000		$ 2,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Aggregate Number of Shares of Common Stock,Percentage								2.50%
Stock Issuance Costs								$ 1,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Description								Both grants have the following vesting schedule: 50% of the options vest over-time with 25% vesting over 12 months of continued service, with the remaining 25% vesting in 12 equal installments thereafter, subject to continued employment. The remaining 50% vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the grant vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Mustang product candidate, (ii) 25% of the grant vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Mustang product candidate, (iii) 25% of the grant vest upon Mustangs achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the grant vest upon Mustangs achievement of a fully-diluted market capitalization of $1,000,000,000.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term								9 years 9 months 22 days
Mustang Bio, Inc [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period Shares warrants Exercised								2,500
Mustang Bio, Inc [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,041,675
Mustang Bio, Inc [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 5.73
Mustang Bio, Inc [Member] | Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								1 year 9 months 18 days		0 years
Share-based Compensation								$ 2,800,000	2,800,000	$ 0
Journey Medical Corporation [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures								320,000
Journey Medical Corporation [Member] | Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								1 year 2 months 12 days		10 months 24 days
Share-based Compensation								$ 200,000	200,000
Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense							800,000	3,400,000	1,900,000
Share-based Compensation						1,900,000	500,000	2,400,000	1,200,000
JMC [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense						73,000	147,000	119,000	328,000
Helocyte Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense						34,000	93,000	$ 81,000	93,000
Helocyte Inc [Member] | Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								0 years		11 days
Share-based Compensation						25,000	68,000	$ 62,000	68,000	$ 33,000
Cellvation Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense						6,000		14,000
Cellvation Inc [Member] | Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation						2,000		5,000
National Holdings Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 183,000		$ 183,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 3.25		$ 3.25
National Holdings Corporation [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage Of Placement Agent Fee		10.00%
Proceeds from Issuance of Private Placement				$ 55,500,000
Warrants Issued				2,134,193
Private Placement Stock Units Shares To Be Issued						10,000		10,000
Percentage Of Shares Issued To Placement Agent				10.00%
National Holdings Corporation [Member] | Mustang Bio, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Proceeds from Issuance of Private Placement			64,000
Payments of Stock Issuance Costs								$ 5,500,000
National Holdings Corporation [Member] | Mustang Bio, Inc [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Proceeds from Issuance of Private Placement			$ 16,000
Common Stock [Member] | Avenue Therapeutics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Issued, Price Per Share						$ 6		$ 6
Stockholders' Equity, Reverse Stock Split								3-For-1
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 2,400,000	1,100,000
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense						2,200,000	1,900,000		2,400,000
General and Administrative Expense [Member] | Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation						200,000	100,000	$ 300,000	100,000
General and Administrative Expense [Member] | Helocyte Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation						8,000	25,000	$ 18,000	25,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								2 years 3 months 18 days
Share-based Compensation						64,000	100,000	$ 100,000	300,000
Restricted Stock [Member] | Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation						400,000	$ 400,000	1,000,000	700,000
Restricted Stock [Member] | JMC [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation						$ 4,000		$ 8,000
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								2 years 4 months 24 days
Share-based Compensation								$ 2,700,000	$ 6,400,000
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common Stock issued in connection with the first ESPP offering								199,995
Common Stock, Capital Shares Reserved for Future Issuance						5		5
Employee Stock Option [Member] | Journey Medical Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%

Related Party Transactions - Sc

Related Party Transactions - Schedule of Effective Date and Equity Fee Payble (Detail)	6 Months Ended
	Jun. 30, 2017
Helocyte Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 20, 2015	[1]
Avenue Therapeutics, Inc. [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Feb. 17, 2015	[1]
Mustang Bio, Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 13, 2015	[1]
Checkpoint Therapeutics, Inc [Member]
Dividends, Paid-in-kind,Percentage	0.00%	[2]
Dividends Payable, Date Declared	Mar. 17, 2015	[1]
Cellvation Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Oct. 31, 2016	[1]
Caelum Biosciences, Inc. [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Jan. 1, 2017	[1]
Cyprium Biosciences, Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 13, 2017	[1]
[1]	Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement.
[2]	Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.

Related Party Transactions - 76

Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Annual Management Services Agreement Fee Income Expense	$ 0
Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	0
Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	0
Helocyte Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 20, 2015
Helocyte Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Helocyte Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Avenue Therapeutics, Inc. [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Feb. 17, 2015
Avenue Therapeutics, Inc. [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Avenue Therapeutics, Inc. [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Mustang Bio, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 13, 2015
Mustang Bio, Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Mustang Bio, Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Checkpoint Therapeutics, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 17, 2015
Checkpoint Therapeutics, Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Checkpoint Therapeutics, Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Cellvation Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Oct. 31, 2016
Cellvation Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Cellvation Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Caelum Biosciences, Inc. [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Jan. 1, 2017
Caelum Biosciences, Inc. [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Caelum Biosciences, Inc. [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Cyprium Biosciences, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 13, 2017
Cyprium Biosciences, Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Cyprium Biosciences, Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Fortress Biotech Inc [Member]
Annual Management Services Agreement Fee Income Expense	(3,500)
Fortress Biotech Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	(1,750)
Fortress Biotech Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	$ (1,750)

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 17, 2017	May 31, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 09, 2016	Mar. 17, 2014
Related Party Transaction [Line Items]
Lease Sharing Agreements Contributions To Property Under Lease					$ 200,000
Equity Method Investment, Ownership Percentage								35.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4.02		$ 4.02
Avenue Therapeutics, Inc. [Member]
Related Party Transaction [Line Items]
Payments for Underwriter Fees					$ 2,300,000
Maximum [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			4.75		$ 4.75
Minimum [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.61		$ 3.61
National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	56.60%		56.60%		56.60%		56.60%
NSC 2017 Note [Member]
Related Party Transaction [Line Items]
Percentage Of Placement Agent Fee	10.00%				10.00%
Warrants on Sale Price of Note,Percentage	10.00%		10.00%		10.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			508,505		508,505
Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		$ 10,000	$ 28,000		$ 48,000
Board of Directors Chairman [Member] | National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage			4.60%		4.60%
TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Payments for Rent			$ 1,600,000		$ 500,000
Due from Related Parties, Current			$ 89,000		$ 89,000
Checkpoint [Member]
Related Party Transaction [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired			2.50%		2.50%
Founders Agreement [Member] | Avenue Therapeutics, Inc. [Member]
Related Party Transaction [Line Items]
Other Fee,Percentage					2.50%
OPPM [Member]
Related Party Transaction [Line Items]
Payments for Rent					$ 100,000
Due from Related Parties, Current			$ 20,000		20,000
Mustang [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		7,500
Avenue [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		$ 5,000
Desk Share Agreements [Member]
Related Party Transaction [Line Items]
Payments for Rent					1,200,000
Desk Share Agreements [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Due from Related Parties, Current			200,000		200,000
Desk Share Agreements [Member] | OPPM [Member]
Related Party Transaction [Line Items]
Due from Related Parties, Current			200,000		200,000
Shared Services Agreement [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Proceeds from Related Party Agreement			400,000	$ 200,000	600,000	$ 300,000
Due from Related Parties, Current			$ 300,000		$ 300,000

Net Capital Requirements of B78

Net Capital Requirements of Broker-Dealer Subsidiaries - Additional Information (Detail)	Mar. 31, 2017USD ($)
Minimum [Member]
Ratio of Indebtedness to Net Capital	1
Maximum [Member]
Ratio of Indebtedness to Net Capital	15
National Securities [Member]
Net Capital	$ 7,924,058
Excess Net Capital at 1000 Percent	7,674,058
Minimum Net Capital Required for Broker-Dealer Subsidiary	250,000
Vfinance Investments [Member]
Net Capital	2,167,442
Excess Net Capital at 1000 Percent	1,167,442
Minimum Net Capital Required for Broker-Dealer Subsidiary	$ 1,000,000
Vfinance Investments [Member] | Minimum [Member]
Ratio of Indebtedness to Net Capital	0.8
Vfinance Investments [Member] | Maximum [Member]
Ratio of Indebtedness to Net Capital	1

Segment Information - Operating

Segment Information - Operating Results by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Net Revenue	$ 50,697	$ 2,230	$ 95,379	$ 2,890
Direct cost of goods	(878)	(324)	(1,347)	(324)
Sales and marketing costs	(2,610)	(1,998)	(4,877)	(3,884)
Research and development	(13,483)	(8,407)	(21,887)	(16,243)
General and administrative	(8,524)	(6,637)	(16,509)	(12,666)
National Expenses	73,890	17,366	136,149	33,117
Segment loss from operations	(23,193)	(15,136)	(40,770)	(30,227)
Segment assets	249,846	98,062	249,846	98,062	$ 170,731
Dermatology Products Sales [Member]
Segment Reporting Information [Line Items]
Net Revenue	4,054	982	6,139	1,364
Direct cost of goods	(878)	(324)	(1,347)	(324)
Sales and marketing costs	(2,610)	(1,998)	(4,877)	(3,884)
Research and development	0	0	0	0
General and administrative	(293)	0	(612)	0
National Expenses	0		0
Segment loss from operations	273	(1,340)	(697)	(2,844)
Segment assets	5,447	3,058	5,447	3,058
Pharmaceutical And Biotechnology Product Development [Member]
Segment Reporting Information [Line Items]
Net Revenue	350	1,248	1,043	1,526
Direct cost of goods	0	0	0	0
Sales and marketing costs	0	0	0	0
Research and development	(13,483)	(8,407)	(21,887)	(16,243)
General and administrative	(8,231)	(6,637)	(15,897)	(12,666)
National Expenses	0		0
Segment loss from operations	(21,364)	(13,796)	(36,741)	(27,383)
Segment assets	167,787	$ 95,004	167,787	$ 95,004
Consolidated [Member]
Segment Reporting Information [Line Items]
Segment loss from operations			(40,770)
National [Member]
Segment Reporting Information [Line Items]
Net Revenue	46,293		88,197
Direct cost of goods	0		0
Sales and marketing costs	0		0
Research and development	0		0
General and administrative	0		0
National Expenses	(48,395)		(91,529)
Segment loss from operations	(2,102)		(3,332)
Segment assets	$ 76,612		$ 76,612

Segment Information - Additiona

Segment Information - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Customer One [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	$ 4.2	$ 0.3	$ 5.3	$ 0.6
Accounts Receivable, Net	2.1		2.1		$ 1.1
Customer Two [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	2.2	0.3	3.8	0.3
Accounts Receivable, Net	$ 0.7		$ 0.7		$ 0.5
Customer Three [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross		$ 0.3		$ 0.3

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - USD ($) $ in Millions	Jul. 05, 2017	Jul. 25, 2017
Subsequent Event [Line Items]
Repayments of Debt	$ 0.6
Avenue Therapeutics, Inc. [Member]
Subsequent Event [Line Items]
Repayments of Debt	3
Proceeds from Collection of Long-term Loans to Related Parties		$ 3.8
N S C [Member]
Subsequent Event [Line Items]
Repayments of Debt	$ 3.6